ACCESS DB # 155618

FOR OFFICIAL USE ONLY

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: June 7, 2005

Art Unit: 1654 Phone Number: 2-0969 Serial Number: 10/049,718

Location (Bldg/Room#): REM 3D19 (Mailbox #): 3C18 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Melanocortin Metallopeptide Constructs, Combinatorial Libraries And Application

Inventors (please provide full names): S. Sharma, T. Shi, Y. Wei, H. Cai

Earliest Priority Date: 6-15-2002

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the follow partial structures:



Please require any hits to have the keywords Rhenium/Re or Technetium/Tc.

(See next page).

****

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

_____ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial ____ Oligomer ____ Score/Length

____ Interference ____ SPDI ____ Encode/Transl

_____ Other (specify)

FOR OFFICIAL USE ONLY

ACCESS DB # 155618

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: _____

Art Unit: 1654 Phone Number: 2-0969 Serial Number: 10/049,748

Location (Bldg/Room#): REM 3D19 (Mailbox #): 3C18 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please also search the following partial sequences in STN:

(Phe / Tyr / Trp) - (Lys / Arg / His) - (Phe / Tyr / Trp) - Cys ; (Phe / Tyr / Trp) - (Lys / Arg / His) - Cys - (Phe / Tyr / Trp)

Cys - (Phe / Tyr / Trp) - (Lys / Arg / His) - (Phe / Tyr / Trp) ; (Lys / Arg / His)(Lys / Arg / His) - (Phe / Tyr / Trp) - Cys

(Gly / Ala / Leu / Ile / Val / Phe / Trp) - (Phe / Tyr / Trp) - Cys - (Phg / Tyr / Trp).

Please require any sequence to have 8 or fewer residues.

Then please use the keywords Rhenium/Re or Technetium/Tc to narrow any hits.

Thank you. JR

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: _____	_____ NA Sequence (#)	_____ STN _____ Dialog
Searcher Phone #: _____	_____ AA Sequence (#)	_____ Questel/Orbit _____ Lexis/Nexis
Searcher Location: _____	_____ Structure (#)	_____ Westlaw _____ WWW/Internet
Date Searcher Picked Up: _____	_____ Bibliographic	____In-house sequence systems
Date Completed: _____	_____ Litigation	____Commercial ____Oligomer ____Score/Length ____ Interference ____ SPDI ____ Encode/Transl
Searcher Prep & Review Time: _____	_____ Fulltext	_____ Other (specify)
Online Time: _____	_____ Other	

Russell
10/049718

=> d l6 que stat
L3 STR







6-28-2005

VAR G1=19/29
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L4 STR







VAR G1=19/29
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L6 27910 SEA FILE=REGISTRY SSS FUL L3 OR L4

100.0% PROCESSED 138233 ITERATIONS 27910 ANSWERS
SEARCH TIME: 00.00.02

=> fil caplus;s l6

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	250.23	1114.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-20.44

FILE 'CAPLUS' ENTERED AT 10:11:11 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Jun 2005 VOL 142 ISS 26
FILE LAST UPDATED: 21 Jun 2005 (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L7 9226 L6

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	1115.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-20.44

FILE 'REGISTRY' ENTERED AT 10:11:27 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2005 HIGHEST RN 852656-52-1
DICTIONARY FILE UPDATES: 21 JUN 2005 HIGHEST RN 852656-52-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> e rhenium/cn 5
E1            1     RHENIPAL/CN
E2            1     RHENISH EARTH/CN
E3            1 --> RHENIUM/CN
E4            1     RHENIUM 0-10, TITANIUM 40-50, VANADIUM 50 (ATOMIC)/CN
E5            1     RHENIUM 0-10, TUNGSTEN 90-100 (ATOMIC)/CN

=> s e3;d ide
L8            1 RHENIUM/CN
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

```
L8   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   7440-15-5  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Rhenium (8CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   NSC 600662
CN   Rhenium element
MF   Re
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
       CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX,
       CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT,
       ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, IFICDB, IFIPAT, IFIUDB, MEDLINE,
       MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, TULSA,
       USPAT2, USPATFULL, VTB
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)


Re


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          17058 REFERENCES IN FILE CA (1907 TO DATE)
           1468 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          17072 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

```
=> e technetium/cn 5
E1            1     TECHNETIC ACID (H6TCO6), HEXALITHIUM SALT/CN
E2            1     TECHNETIC ACID (HTCO4)/CN
E3            1 --> TECHNETIUM/CN
E4            1     TECHNETIUM (99MTC) APCITIDE/CN
E5            1     TECHNETIUM (99MTC) FANOLESOMAB/CN

=> s e3;d ide
L9            1 TECHNETIUM/CN
```

```
L9   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   7440-26-8  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Technetium (8CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Masurium
CN   Technetium element
MF   Tc
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
       CHEMLIST, CIN, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, ENCOMPLIT,
       ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE,
       MRCK*, NIOSHTIC, PROMT, TOXCENTER, TULSA, USPAT2, USPATFULL, VTB
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)


Tc


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

           3921 REFERENCES IN FILE CA (1907 TO DATE)
            647 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
           3927 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> fil caplus;s l7 and (l8 or l9 or rhenium or re or technetium or tc)
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    13.74    1129.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -20.44

FILE 'CAPLUS' ENTERED AT 10:12:25 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Jun 2005  VOL 142 ISS 26
FILE LAST UPDATED: 21 Jun 2005  (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


         17072 L8
          3927 L9
         33299 RHENIUM
             8 RHENIUMS
         33299 RHENIUM
                 (RHENIUM OR RHENIUMS)
        131758 RE
          9766 RES
        141147 RE
                 (RE OR RES)
         16509 TECHNETIUM
             1 TECHNETIUMS
         16509 TECHNETIUM
                 (TECHNETIUM OR TECHNETIUMS)
         95611 TC
          1350 TCS
         96655 TC
                 (TC OR TCS)
L10        173 L7 AND (L8 OR L9 OR RHENIUM OR RE OR TECHNETIUM OR TC)

=> fil caplus;s l7 and (l8 or l9 or rhenium or  technetium )
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 8.01 1137.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -20.44

FILE 'CAPLUS' ENTERED AT 10:12:41 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Jun 2005 VOL 142 ISS 26
FILE LAST UPDATED: 21 Jun 2005 (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
         17072 L8
          3927 L9
         33299 RHENIUM
             8 RHENIUMS
         33299 RHENIUM
                 (RHENIUM OR RHENIUMS)
         16509 TECHNETIUM
             1 TECHNETIUMS
         16509 TECHNETIUM
                 (TECHNETIUM OR TECHNETIUMS)
L11        133 L7 AND (L8 OR L9 OR RHENIUM OR  TECHNETIUM )

=> s (elanocortin metallopepide or combinator? librar?) and l11
             0 ELANOCORTIN
             0 METALLOPEPIDE
             0 ELANOCORTIN METALLOPEPIDE
                 (ELANOCORTIN(W)METALLOPEPIDE)
         19524 COMBINATOR?
         84403 LIBRAR?
          8584 COMBINATOR? LIBRAR?
                 (COMBINATOR?(W)LIBRAR?)
L12          4 (ELANOCORTIN METALLOPEPIDE OR COMBINATOR? LIBRAR?) AND L11

=> s (melanocortin metallopepide or combinator? librar?) and l11
          2044 MELANOCORTIN
           294 MELANOCORTINS
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

```
          2090 MELANOCORTIN
                 (MELANOCORTIN OR MELANOCORTINS)
             0 METALLOPEPIDE
             0 MELANOCORTIN METALLOPEPIDE
                 (MELANOCORTIN(W)METALLOPEPIDE)
         19524 COMBINATOR?
         84403 LIBRAR?
          8584 COMBINATOR? LIBRAR?
                 (COMBINATOR?(W)LIBRAR?)
L13          4 (MELANOCORTIN METALLOPEPIDE OR COMBINATOR? LIBRAR?) AND L11

=> d l13 1-4 ibib abs hitstr
```

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:430952 CAPLUS
DOCUMENT NUMBER: 141:19610
TITLE: Crystal structure, cloning and sequence of short-chain dehydrogenase/reductase from Streptococcus pneumoniae and Pseudomonas aeruginosa and applications in drug discovery
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Virag, Cristina; Alam, Muhammad Zahoor; Domagala, Megan; Pinder, Benjamin; Houston, Simon; Nethery, Kathleen; Ng, Ivy; Clarke, Teresa; Kimber, Matthew
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 374 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004044189	A2	20040527	WO 2003-CA1715	20031112
WO 2004044189	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-425568P P 20021112

AB The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochem. and biophys. characteristics of those polypeptides. Reliable, high throughput methods are developed to identify, express, and purify antimicrobial targets from Streptococcus pneumoniae and Pseudomonas aeruginosa. The nucleotide sequences and the encoded amino acid sequences are provided for short-chain dehydrogenase/reductase from S. pneumoniae and P. aeruginosa. The invention also provides bioinformatic, biochem. and biophys. characteristics of those polypeptides, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog. Crystal structures and atomic structure coordinates of the short-chain dehydrogenase/reductase from S. pneumoniae and P. aeruginosa are disclosed. The structural data are used for drug screening and drug design.

IT 7440-15-5, Rhenium, uses
RL: NUU (Other use, unclassified); USES (Uses)
(heavy atom label; crystal structure, cloning and sequence of short-chain dehydrogenase/reductase from Streptococcus pneumoniae and Pseudomonas aeruginosa and drug discovery use)

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

—NH_2

PAGE 2-A



L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Re

IT 697248-10-5
RL: PRP (Properties)
(unclaimed sequence; crystal structure, cloning and sequence of short-chain dehydrogenase/reductase from Streptococcus pneumoniae and Pseudomonas aeruginosa and applications in drug discovery)
RN 697248-10-5 CAPLUS
CN L-Lysine, glycyl-L-leucyl-L-methionyl-L-alanyl-L-valyl-L-threonyl-L-arginyl-L-cysteinyl-L-phenylalanyl-L-leucyl-L-prolyl-L-alanyl-L-methionyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:380441 CAPLUS
DOCUMENT NUMBER: 135:519
TITLE: Opioid metallopeptide compositions and methods
INVENTOR(S): Sharma, Shubh D.; Wei, Yang; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036006	A1	20010525	WO 2000-US31797	20001117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-166582P P 19991119

AB Metallopeptides and metallopeptide combinatorial libraries specific for opioids receptors are provided, for use in biol., pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.

IT 179034-19-6D, rhenium oxide complexes
340964-82-1D, rhenium oxide complexes
340964-84-3D, rhenium oxide complexes
340964-88-7D, rhenium oxide complexes
340964-90-1D, rhenium oxide complexes
340965-06-2D, rhenium oxide complexes
340965-08-4D, rhenium oxide complexes
340965-10-8D, rhenium oxide complexes
340965-13-1D, rhenium oxide complexes
340965-17-5D, rhenium oxide complexes
340965-21-1D, rhenium oxide complexes
340965-23-3D, rhenium oxide complexes
340965-27-7D, rhenium oxide complexes
340965-35-7D, rhenium oxide complexes
340965-38-0D, rhenium oxide complexes
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(conformationally restricted peptides and metallo constructs specific for opioid receptors)
RN 179034-19-6 CAPLUS
CN L-Cysteine, L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 340964-82-1 CAPLUS
CN L-Cysteinamide, L-tyrosyl-L-alanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 340964-84-3 CAPLUS
CN L-Cysteinamide, L-tyrosyl-L-cysteinylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 340964-88-7 CAPLUS
CN Glycinamide, L-tyrosyl-L-cysteinyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

$-NH_2$

RN 340965-10-8 CAPLUS
CN L-Cysteinamide, (αS)-α-amino-4-hydroxybenzenebutanoyl-β-alanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

$-NH_2$

RN 340965-13-1 CAPLUS
CN D-Cysteinamide, (αS)-α-amino-4-hydroxybenzenebutanoyl-β-alanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 340964-90-1 CAPLUS
CN L-Cysteinamide, L-tyrosylglycyl-D-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 340965-06-2 CAPLUS
CN L-Cysteinamide, L-tyrosyl-β-alanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

$-NH_2$

RN 340965-08-4 CAPLUS
CN D-Cysteinamide, L-tyrosyl-β-alanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



PAGE 1-A

PAGE 1-B

$\backslash NH_2$

RN 340965-17-5 CAPLUS
CN D-Cysteinamide,
N4-L-tyrosyl-(2S)-2,4-diaminobutanoylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

$\backslash NH_2$

RN 340965-21-1 CAPLUS
CN D-Cysteinamide, N5-L-tyrosyl-L-ornithylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 340965-23-3 CAPLUS
CN D-Cysteinamide, (αS)-α-amino-4-hydroxybenzenebutanoylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 340965-27-7 CAPLUS
CN L-Cysteinamide, L-tyrosyl-L-valyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 340965-35-7 CAPLUS
CN L-Cysteine, L-tyrosyl-L-alanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 340965-38-0 CAPLUS
CN L-Cysteine, D-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:137478 CAPLUS
DOCUMENT NUMBER: 134:188233
TITLE: Melanocortin metallopeptide constructs, **combinatorial libraries**, and applications
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Yang, Wei; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013112	A1	20010222	WO 2000-US16396	20000615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379647	AA	20010222	CA 2000-2379647	20000615
EP 1208377	A1	20020529	EP 2000-944681	20000615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004519410	T2	20040702	JP 2001-517163	20000615
PRIORITY APPLN. INFO.:			US 1999-148994P	P 19990812
			WO 2000-US16396	W 20000615

OTHER SOURCE(S): MARPAT 134:188233
AB Metallopeptides and metallopeptide **combinatorial libraries** specific for melanocortin receptors are provided, for use in biol., pharmaceutical and related applications. The metallopeptides and **combinatorial libraries** are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.
IT **327603-57-6P 327603-62-3P 327607-55-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanocortin metallopeptide constructs, **combinatorial libraries**, and applications)
RN 327603-57-6 CAPLUS
CN L-Tryptophanamide, N-acetyl-L-histidyl-L-phenylalanyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 327603-62-3 CAPLUS
CN L-Tryptophanamide, N-acetyl-L-histidyl-D-phenylalanyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327607-55-6 CAPLUS
CN L-Tryptophanamide, N-acetyl-D-alanyl-L-histidyl-L-cysteinyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **7440-15-5D, Rhenium**, complexes with peptidic compds., biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanocortin metallopeptide constructs, **combinatorial libraries**, and applications)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Re

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PROC (Process); USES (Uses)
(metallopeptide **combinatorial libraries** synthesis and applications)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Re

RN 7440-26-8 CAPLUS
CN Technetium (8CI, 9CI) (CA INDEX NAME)

Tc

IT **276864-29-0P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(metallopeptide **combinatorial libraries** synthesis and applications)
RN 276864-29-0 CAPLUS
CN D-Tryptophanamide, N-acetyl-D-histidyl-3-(2-naphthalenyl)-D-alanyl-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **103784-95-8DP**, complex with **rhenium**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(metallopeptide **combinatorial libraries** synthesis and applications)
RN 103784-95-8 CAPLUS
CN L-Cysteine, L-tyrosyl-L-cysteinylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:421334 CAPLUS
DOCUMENT NUMBER: 133:55661
TITLE: Metallopeptide **combinatorial libraries** and synthesis and applications
INVENTOR(S): Sharma, Shubh D.; Shi, Yiqun
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000036136	A1	20000622	WO 1999-US29743	19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2353072	AA	20000622	CA 1999-2353072	19991214
EP 1141375	A1	20011010	EP 1999-964263	19991214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536295	T2	20021029	JP 2000-588384	19991214
AU 760257	B2	20030508	AU 2000-20541	19991214
US 2002012948	A1	20020131	US 2001-883069	20010614
PRIORITY APPLN. INFO.:			US 1998-112235P	P 19981214
			US 1995-476652	A 19950607
			US 1996-660697	A 19960605
			WO 1999-US29743	W 19991214

AB Metallopeptide **combinatorial libraries** and methods of making libraries and metallopeptides are provided for use in biol., pharmaceutical and related applications. The **combinatorial libraries** are made of peptides, peptidomimetics and peptide-like constructs, and include a metal ion-binding region thereof which includes at least one orthogonal sulfur-protecting group, in which the peptide, peptidomimetic or construct is conformationally fixed on deprotection of the sulfur and complexation of the metal ion-binding region with a metal ion. Methods of synthesis of these metallopeptides are described. Thereafter the library members may be screened to select those with the desired specificity and affinity.
IT **7440-15-5, Rhenium**, biological studies **7440-26-8, Technetium**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study);

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil medline,biosis,embase,caplus;s sharma s?/au;s shi y?/au;s wei y?/au;s cai
h?/au
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    40.46    1177.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -2.92     -23.36

FILE 'MEDLINE' ENTERED AT 10:15:10 ON 22 JUN 2005

FILE 'BIOSIS' ENTERED AT 10:15:10 ON 22 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:15:10 ON 22 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 10:15:10 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


L14        4135 FILE MEDLINE
L15        6562 FILE BIOSIS
L16        3621 FILE EMBASE
L17        6387 FILE CAPLUS

TOTAL FOR ALL FILES
L18       20705 SHARMA S?/AU


L19        2041 FILE MEDLINE
L20        2302 FILE BIOSIS
L21        1535 FILE EMBASE
L22        6286 FILE CAPLUS

TOTAL FOR ALL FILES
L23       12164 SHI Y?/AU


L24        1104 FILE MEDLINE
L25        1290 FILE BIOSIS
L26         872 FILE EMBASE
L27        4438 FILE CAPLUS

TOTAL FOR ALL FILES
L28        7704 WEI Y?/AU


L29         413 FILE MEDLINE
L30         515 FILE BIOSIS
L31         304 FILE EMBASE
L32        1330 FILE CAPLUS

TOTAL FOR ALL FILES
```

```
L33        2562 CAI H?/AU

=> s l18 and l23 and l28 and l33
L34           0 FILE MEDLINE
L35           0 FILE BIOSIS
L36           0 FILE EMBASE
L37           0 FILE CAPLUS

TOTAL FOR ALL FILES
L38           0 L18 AND L23 AND L28 AND L33

=> s l7 and (l18 or l23 or l28 or l33)
TOO MANY TERMS FOR FILE CROSSOVER IN L6
There are limits on the size of an answer set being crossed over from
one file to another.  Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> fil caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                10.56    1188.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -23.36

FILE 'CAPLUS' ENTERED AT 10:15:50 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Jun 2005  VOL 142 ISS 26
FILE LAST UPDATED: 21 Jun 2005  (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l7 and (l18 or l23 or l28 or l33)
L39           78 L7 AND (L17 OR L22 OR L27 OR L32)

=> s (melanocortin metallopepide or combinator? librar?) and l39
          2044 MELANOCORTIN
           294 MELANOCORTINS
          2090 MELANOCORTIN
```

```
                (MELANOCORTIN OR MELANOCORTINS)
             0 METALLOPEPIDE
             0 MELANOCORTIN METALLOPEPIDE
                (MELANOCORTIN(W)METALLOPEPIDE)
         19524 COMBINATOR?
         84403 LIBRAR?
          8584 COMBINATOR? LIBRAR?
                (COMBINATOR?(W)LIBRAR?)
L40           3 (MELANOCORTIN METALLOPEPIDE OR COMBINATOR? LIBRAR?) AND L39

=> s l40 not l13
L41           0 L40 NOT L13

=> s l39 not l40
L42          75 L39 NOT L40

=> d 1-75 cbib abs
```

L42 ANSWER 1 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2005:59906 Document No. 142:148744 Identification of target-specific folding
sites in proteins using metallopeptide derivatives of sequences of interest. **Sharma, Shubh D.; Shi, Yi-qun** (USA). U.S. Pat. Appl. Publ. US 2005014193 A1 20050120, 75 pp. (English). CODEN: USXXCO. APPLICATION: US 2003-464117 20030617.

AB A method of identifying peptides that take up folded conformations and that bind to specific protein target is described. The method involves creating a systematic series of substitution deriva. of the peptide. These deriva. use amino acids or amino acid analogs containing a nitrogen or sulfur atom that can bind to a metal atom. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The structure of the metallopeptide can then be determined and a novel pharmacophore can be identified. The invention provides for defined pharmacophores of receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.

L42 ANSWER 2 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:1060669 Document No. 142:34829 Knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs. **Sharma, Shubh D.; Shi, Yi-Qun; Bastos, Margarita; Rajpurohit, Ramesh; Cai, Hui-Zhi** (Palatin Technologies, Inc., USA). U.S. Pat. Appl. Publ. US 2004248212 A1 20041209, 43 pp., Cont.-in-part of U.S. Ser. No. 464,117. (English). CODEN: USXXCO. APPLICATION: US 2004-769695 20040130. PRIORITY: US 2000-PV256842 20001219; US 2001-PV304835 20010711; US 2001-PV327835 20011004; WO 2001-US50075 20011219; US 2003-PV444129 20030131; US 2003-464117 20030617.

AB The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of a peptide or protein. A residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of the peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide with a conformationally fixed and predictable secondary structure of the residues involved in metal ion complexation. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality. The method is exemplified by α-MSH and bombesin analogs containing L-/D-cysteine insertions or substitutions complexed to the rhenium metal ion, and their binding to their resp. receptors.

L42 ANSWER 3 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:754416 Document No. 141:282785 Fusion proteins comprising a targeting portion and an immune response triggering portion and uses as antitumor agents. Wagner, Thomas E.; **Wei, Yanshang** (Greenville Hospital System, USA). PCT Int. Appl. WO 2004078137 A2 20040916, 47 pp. DESIGNATED STATES: W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US6450 20040304. PRIORITY: US 2003-PV451253 20030304.

AB The present invention provides an antitumor agent comprising a targeting portion and an immune response triggering portion. The targeting portion may be an antibody fragment or a tumor vasculature binding peptide which comprises arginine-glycine-aspartate (RGD), asparagine-glycine-arginine(NGR), or glycine-serine-leucine (GSL). The immune response triggering portion may be an Fc fragment of IgG (IgG), a fragment of the Fc fragment of IgG that exhibits the same biol. function as the Fc region, or the extracellular domain of foreign major histocompatibility complex (MHC). The antitumor agent is useful for inhibiting tumor growth, inhibiting tumor angiogenesis and treating diseases associated with neovascularization.

L42 ANSWER 4 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:740117 Document No. 141:256945 Knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs. **Sharma, Shubh D.; Shi, Yi-Qun**; Rajpurohit, Ramesh; Bastos, Margarita; **Cai, Hui-Zhi** (Palatin Technologies, Inc., USA). PCT Int. Appl. WO 2004075830 A2 20040910, 78 pp. DESIGNATED STATES: W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US2933 20040202. PRIORITY: US 2003-PV444129 20030131; US 2004-769695 20040130.

AB The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. A residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of the peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide with a conformationally fixed and predictable secondary structure of the residues involved in metal ion complexation. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality. The method is exemplified by α-MSH and bombesin analogs containing L-/D-cysteine insertions or substitutions complexed to the rhenium metal ion, and their binding to their resp. receptors.

L42 ANSWER 5 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:584481 Document No. 141:135218 Protein and cDNA sequences of a novel human secreted protein primarily expressed in endometrial tumors. Ruben, Steven M.; Ni, Jian; Rosen, Craig A.; Ebner, Reinhard; Young, Paul; Moore, Paul A.; Feng, Ping; Lafleur, David W.; Olsen, Henrik S.; **Shi, Yanggu**; Brewer, Laurie A.; Greene, John M.; Ferrie, Ann M.; Yu, Guo-liang (Human Genome Sciences, Inc., USA). Eur. Pat. Appl. EP 1439189 A2 20040721, 292 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY. (English). CODEN: EPXXDW. APPLICATION: EP 2004-8119 19980611. PRIORITY: US 97-PV49547; 19970613; US 97-PV49548; 19970613; US 97-PV49549; 19970613; US 97-PV49550; 19970613; US 97-PV49566; 19970613; US 97-PV49606; 19970613; US 97-PV49607; 19970613; US 97-PV49608; 19970613; US 97-PV49609; 19970613; US 97-PV49610; 19970613; US 97-PV49611; 19970613; US 97-PV50901; 19970613; US 97-PV52989; 19970613; US 97-PV51919; 19970708; US 97-PV55984; 19970818; US 97-PV58665; 19970912; US 97-PV58668; 19970912; US 97-PV58669; 19970912; US 97-PV58750; 19970912; US 97-PV58971; 19970912.
AB The present invention relates to a human secreted protein characterized by SEQ IDs 26 and 126, and primary expressed in endometrial tumors. Also provided are vectors, host cells, antibodies, and recombinant methods for producing the proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this protein.

L42 ANSWER 6 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:339021 Document No. 140:422271 Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Li, Jinhua; Ji, Jianfei; Holmes, Lillia M.; Burgin, Kelly E.; Barton, Lori B.; Yu, Xianzhong; Wagner, Thomas E.; **Wei, Yanzhang** (Oncology Research Institute, Greenville Hospital System, Greenville, SC, 29605, USA). Cancer Gene Therapy, 11(5), 363-370 (English) 2004. CODEN: CGTHEG. ISSN: 0929-1903. Publisher: Nature Publishing Group.
AB Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The αvβ3 integrins have been specifically associated with angiogenesis in tumors. By using bacteriophage display technol., a group of peptides containing the RGD (Arg-Gly-Asp) motif have high-binding affinity to the αvβ3 integrins in tumors. In this study, the authors designed a fusion protein containing the RGD sequence and the Fc fragment of mouse IgG to target the Fc portion of IgG to the tumor vasculature to elicit an antiangiogenesis immune response. In vivo angiogenesis and tumor studies demonstrated that the fusion protein (RGD/mFc) inhibited tumor angiogenesis and tumor growth and improved overall survival. This approach may generate new therapeutic agents for solid tumor treatment.

L42 ANSWER 7 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:195308 Document No. 140:194487 Genes for human proteins with features typical of secreted proteins with possible diagnostic and therapeutic use. Ruben, Steven M.; Rosen, Craig A.; Soppet, Daniel R.; Carter, Kenneth C.; Bednarik, Daniel P.; Endress, Gregory A.; Yu, Guo-Liang; Ni, Jian; Feng, Ping; Young, Paul E.; Greene, John M.; Ferrie, Ann M.; Duan, D. Roxanne; Hu, Jing-Shan; Florence, Kimberly A.; Olsen, Henrik S.; Fischer, Carrie L.; Ebner, Reinhard; Brewer, Laurie A.; Moore, Paul A.; **Shi, Yanggu**; LaFleur, David W.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla (USA). U.S. Pat. Appl. Publ. US 2003049618 A1 20030313, 260 pp., Cont.-in-part of U.S. 6,420,526. (English). CODEN: USXXCO. APPLICATION: US 2001-809391 20010316. PRIORITY: US 1997-PV40162 19970307; US 1997-PV40333 19970307; US 1997-PV38621 19970307; US 1997-PV40626 19970307; US 1997-PV40334 19970307; US 1997-PV40336 19970307; US 1997-PV40163 19970307; US 1997-PV47600 19970523; US 1997-PV47615 19970523; US 1997-PV47597 19970523; US 1997-PV47502 19970523; US 1997-PV47633 19970523; US 1997-PV47583 19970523; US 1997-PV47617 19970523; US 1997-PV47618 19970523; US 1997-PV47503 19970523; US 1997-PV47592 19970523; WO 1998-US4493 19980306; US 1998-149476 19980908; US 2000-PV190068 20000317.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L42 ANSWER 8 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:182582 Document No. 140:212072 Cloning and cDNA and deduced amino acid sequences of 123 human secreted proteins. Fischer, Carrie L.; Rosen, Craig A.; Soppet, Daniel R.; Ruben, Steven M.; Kyaw, Hla; Li, Yi; Zeng, Zhizhen; Lafleur, David W.; Moore, Paul A.; **Shi, Yanggu**; Olsen, Henrik; Ebner, Reinhard; Birse, Charles E. (USA). U.S. Pat. Appl. Publ. US 2004044191 A1 20040304, 372 pp., Cont.-in-part of U.S. Ser. No. 227,357. (English). CODEN: USXXCO. APPLICATION: US 2001-973278 20011010. PRIORITY: US 97-PV51926; 19970708; US 97-PV52793; 19970708; US 97-PV51925; 19970708; US 97-PV51929; 19970708; US 97-PV52803; 19970708; US 97-PV52732; 19970708; US 97-PV51931; 19970708; US 97-PV51932; 19970708; US 97-PV51916; 19970708; US 97-PV51930; 19970708; US 97-PV51918; 19970708; US 97-PV51920; 19970708; US 97-PV52733; 19970708; US 97-PV52795; 19970708; US 97-PV51919; 19970708; US 97-PV51928; 19970708; US 97-PV55964; 19970818; US 97-PV56360; 19970818; US 97-PV55684; 19970818; US 97-PV55984; 19970818.
AB The present invention relates to 123 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 9 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:142843 Document No. 140:158660 Cloning and cDNA and deduced amino acid sequences of 98 human secreted proteins. Komatsoulis, George A.; Rosen, Craig A.; Ruben, Steven M.; Duan, D. Roxanne; Moore, Paul A.; Shi, Yanggu; Lafleur, David W.; Wei, Ying-Fei (USA). U.S. Pat. Appl. Publ. US 2004034196 A1 20040219, 234 pp., Cont.-in-part of U.S. 6,476,195. (English). CODEN: USXXCO. APPLICATION: US 2003-351334 20030127. PRIORITY: US 1998-PV94657 19980730; US 1998-PV95486 19980805; US 1998-PV95454 19980806; US 1998-PV95455 19980806; US 1998-PV96319 19980812; WO 1999-US17130 19990729; US 2000-489847 20000124; US 2002-PV350898 20020125.
AB The present invention relates to 98 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 10 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:86481 Document No. 140:337550 A rapid method for quantitative prediction of high affinity CTL epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A*0201. Lin, Zhihua; Wu, Yuzhang; Wei, Yunlong; Ni, Bing; Zhu, Bo; Wang, Li (PLA, Institute of Immunology, Third Military Medical University, Chongqing, Peop. Rep. China). Letters in Peptide Science, 10(1), 15-23 (English) 2003. CODEN: LPSCEM. ISSN: 0929-5666. Publisher: Kluwer Academic Publishers.
AB It would be useful to develop a method to rapidly identify peptide epitopes for vaccine development. In this paper, empirical three-dimensional quant. structure-affinity relation (3D-QSAR) methods were used to study the relation between the three dimensional structural parameters (the isotropic surface area, ISA, and the electronic charge index, ECI) of the HLA-A*0201 binding peptide and the HLA-A*0201/peptide binding affinities. A set of 102 peptides having affinity with the class I MHC HLA-A*0201 mol. was used as training set. A test set of 40 peptides was used to determine the predictive value of the models. The 3D-QSAR models gave a q2 = 0.5724 and high r2pred = 0.6955. According to the standard regression coeffs., it is known that the hydrophobic interactions (in these studies, the ISA is highly correlative with the hydrophobic property) play a dominant role in peptide-MHC mol. binding, and also which amino acid residue with what property is needed at specific position of the peptide. The approach the authors have taken is highly complementary to the many excellent methods described in refs. and appears highly predictive. It is a rapid and convenient method for detecting high affinity peptide epitopes.

L42 ANSWER 11 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2004:3693 Document No. 140:72162 Cloning and cDNA and deduced amino acid sequences of 50 human secreted proteins. Moore, Paul A.; Ruben, Steven M.; Lafleur, David W.; Shi, Yanggu; Rosen, Craig A.; Olsen, Henrik S.; Ebner, Reinhard; Brewer, Laurie A. (Human Genome Sciences, Inc., USA). U.S. Pat. Appl. Publ. US 2004002591 A1 20040101, 383 pp., Cont.-in-part of U.S. Ser. No. 722,329. (English). CODEN: USXXCO. APPLICATION: US 2002-47021 20020117. PRIORITY: US 1997-PV57626 19970905; US 1997-PV57663 19970905; US 1997-PV57669 19970905; US 1997-PV58666 19970912; US 1997-PV58667 19970912; US 1997-PV58973 19970912; US 1997-PV58974 19970912; US 1998-PV90112 19980622; WO 1998-US18360 19980903; US 1999-262109 19990304; US 2000-722329 20001128; US 2001-PV262066 20010118.
AB The present invention relates to 50 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 12 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:950031 Document No. 140:13734 Cloning and cDNA and deduced amino acid sequences of 28 human secreted proteins. Rosen, Craig A.; Ruben, Steven M.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla; Fischer, Carrie L.; Li, Haodong; Soppet, Daniel R.; Gentz, Reiner L.; Wei, Ying-Fei; Moore, Paul A.; Young, Paul E.; Greene, John M.; Ferrie, Ann M.; Hastings, Gregg A. (USA). U.S. Pat. Appl. Publ. US 2003225009 A1 20031204, 320 pp., Cont.-in-part of U.S. Ser. No. 852,659. (English). CODEN: USXXCO. APPLICATION: US 2002-58993 20020130. PRIORITY: US 1997-PV40762 19970314; US 1997-PV40710 19970314; US 1997-PV50934 19970530; US 1997-PV48100 19970530; US 1997-PV48357 19970530; US 1997-PV48189 19970530; US 1997-PV48970 19970606; US 1997-PV57765 19970905; US 1997-PV68368 19971219; WO 1998-US4858 19980312; US 1998-152060 19980911; US 2001-PV265583 20010202; US 2001-852659 20010511; US 2001-852797 20010511; US 2001-853161 20010511.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. The present invention relates to 28 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 13 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:757376 Document No. 139:272072 Cloning and cDNA and deduced amino acid sequences of 207 human secreted proteins. Ni, Jian; Ebner, Reinhard; Moore, Paul A.; Olsen, Henrik S.; Rosen, Craig A.; Ruben, Steven A.; Soppet, Daniel R.; Young, Paul E.; **Shi, Yanggu**; Florence, Kimberly A.; **Wei, Yin-Fei**; Florence, Charles; Hu, Jing-Shan; Li, Yi (USA). U.S. Pat. Appl. Publ. US 2003181692 A1 20030925, 328 pp., Cont.-in-part of Appl. No. PCT/US01/05614. (English). CODEN: USXXCO. APPLICATION: US 2001-933767 20010822. PRIORITY: US 97-PV57776; 19970905; US 97-PV57778; 19970905; US 97-PV57629; 19970905; US 97-PV57628; 19970905; US 97-PV57777; 19970905; US 97-PV57634; 19970905; US 97-PV57645; 19970905; US 97-PV57642; 19970905; US 97-PV57668; 19970905; US 97-PV57635; 19970905; US 97-PV57627; 19970905; US 97-PV57667; 19970905; US 97-PV57666; 19970905; US 97-PV57764; 19970905; US 97-PV57643; 19970905; US 97-PV57769; 19970905; US 97-PV57763; 19970905; US 97-PV57650; 19970905; US 97-PV57584; 19970905; US 97-PV57647; 19970905.
AB The present invention relates to 207 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 14 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:737282 Document No. 139:256337 Human serine protease sequence homologs and cDNAs encoding them and related antibodies for therapeutic and diagnostic use. **Shi, Yanggu**; Ruben, Steven M.; Ni, Jian; Young, Paul E. (Human Genome Sciences, Inc., USA). U.S. Pat. Appl. Publ. US 2003175938 A1 20030918, 133 pp., Cont.-in-part of U.S. Ser. No. 125,459. (English). CODEN: USXXCO. APPLICATION: US 2002-319519 20021216. PRIORITY: US 1999-PV133239 19990507; US 1999-PV135163 19990520; US 1999-PV147005 19990803; US 1999-PV152935 19990909; US 1999-PV162979 19991101; US 2000-PV189025 20000314; WO 2000-US12207 20000505; US 2000-597843 20000620; US 2000-597839 20000620; US 2000-597842 20000620; US 2001-804156 20010313; US 2001-946633 20010906; US 2002-67761 20020208; US 2002-125459 20020419.
AB The present invention relates to protein and cDNA sequences of 10 novel human serine proteinase sequence homologs. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides. Identification of the clones and anal. of tissue distribution of mRNAs by multiple tissue Northern blot are reported.

L42 ANSWER 15 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:696519 Document No. 139:208874 Cloning and cDNA and deduced amino acid sequences of 28 human secreted proteins. Ruben, Steven M.; Feng, Ping; Lafleur, David W.; Moore, Paul A.; **Shi, Yanggu**; Kyaw, Hla; Li, Yi; Zeng, Zhizhen; Carter, Kenneth C.; Endress, Gregory A.; **Wei, Ying-Fei**; Fan, Ping; Rosen, Craig A. (Human Genome Sciences, Inc., USA). U.S. Pat. Appl. Publ. US 2003166541 A1 20030904, 308 pp., Cont.-in-part of U.S. Ser. No. 236,557, abandoned. (English). CODEN: USXXCO. APPLICATION: US 2002-160162 20020604. PRIORITY: US 97-PV54209; 19970730; US 97-PV54211; 19970730; US 97-PV54212; 19970730; US 97-PV54213; 19970730; US 97-PV54214; 19970730; US 97-PV54215; 19970730; US 97-PV54217; 19970730; US 97-PV54218; 19970730; US 97-PV54234; 19970730; US 97-PV54236; 19970730; US 97-PV55969; 19970818; US 97-PV55972; 19970818; US 97-PV55968; 19970818; US 97-PV56534; 19970819; US 97-PV56543; 19970819; US 97-PV56554; 19970819; US 97-PV56561; 19970819; US 97-PV56727; 19970819; US 97-PV56729; 19970819; US 97-PV56730; 19970819.
AB The present invention relates to 83 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 16 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:532251 Document No. 139:96371 Nucleic acids encoding 12 human secreted proteins and their diagnostic and therapeutic uses. Ni, Jian; Young, Paul E.; Kenny, Joseph J.; Olsen, Henrik S.; Moore, Paul A.; **Wei, Ying-Fei**; Greene, John M.; Ruben, Steven M. (USA). U.S. Pat. Appl. Publ. US 2003129685 A1 20030710, 439 pp., Cont.in-part of Appl. No. PCT/US99/25031. (English). CODEN: USXXCO. APPLICATION: US 2001-836353 20010418. PRIORITY: US 1998-PV105971 19981028; WO 1999-US25031 19991027; US 2000-PV198407 20000419.
AB The present invention relates to 12 novel human secreted proteins and isolated cDNAs containing the coding regions of the genes encoding such proteins. Homol. comparisons, tissue expression profiles, and chromosome locations are provided for the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L42 ANSWER 17 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:415106 Document No. 139:193128 Synleurin, a novel leucine-rich repeat protein that increases the intensity of pleiotropic cytokine responses. Wang, Wei; Yang, Yan; Li, Lei; **Shi, Yanggu** (Human Genome Sciences, Inc., Rockville, MD, 20850, USA). Biochemical and Biophysical Research Communications, 305(4), 981-988 (English) 2003. CODEN: BBRCA9. ISSN: 0006-291X. Publisher: Elsevier Science.

AB The authors have identified and characterized a novel single span transmembrane leucine-rich repeat protein, synleurin, that renders cells highly sensitive to the activation by cytokines and lipopolysaccharide (LPS). The major part of the extracellular domain consists of a leucine-rich repeats (LRR) cassette. The LRR central core has 12 analogous LRR repeating modules arranged in a seamless tandem array. The LRRs are most homologous to that of chondroadherin, insulin-like growth factor binding proteins, platelet glycoprotein V, slits, and toll-like receptors. Synleurin expression was detected at low levels in many tissues, including smooth muscle, brain, uterus, pancreas, cartilage, adipose, spleen, and testis. When synleurin is ectopically expressed in transfected cells, the cells exhibit amplified responses to bFGF, EGF, PDGF-B, IGF-1, IGF-2, and LPS. Synleurin gene (slrn) maps to human chromosome at 5q12. The name synleurin reflects its synergistic effect on cytokine stimulation and its prominent leucine-rich repeats.

L42 ANSWER 18 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:413994 Document No. 138:397343 Cloning and cDNA and deduced amino acid sequences of 97 human secreted proteins. Ruben, Steven M.; Florence, Kimberly A.; Ni, Jian; Rosen, Craig A.; Carter, Kenneth C.; Moore, Paul A.; Olsen, Henrik S.; **Shi, Yanggu**; Young, Paul E.; **Wei, Ying-fei**; Brewer, Laurie A.; Soppet, Daniel R.; Lafleur, David W.; Endress, Gregory A.; Ebner, Reinhard; Birse, Charles E. (USA). U.S. Pat. Appl. Publ. US 2003100051 A1 20030529, 453 pp., Cont.-in-part of U.S. Ser. No. 892,877. (English). CODEN: USXXCO. APPLICATION: US 2001-948783 20010910. PRIORITY: US 1998-PV85093 19980512; US 1998-PV85094 19980512; US 1998-PV85105 19980512; US 1998-PV85180 19980512; US 1998-PV85927 19980518; US 1998-PV85906 19980518; US 1998-PV85920 19980518; US 1998-PV85924 19980518; US 1998-PV85922 19980518; US 1998-PV85923 19980518; US 1998-PV85921 19980518; US 1998-PV85925 19980518; US 1998-PV85928 19980518; WO 1999-US9847 19990506; US 1999-437658 19991110; US 2000-PV231846 20000911; US 2001-892877 20010628.

AB The present invention relates to 97 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 19 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:222364 Document No. 138:249933 Cloning and cDNA and deduced amino acid sequences of 12 human secreted proteins. Ni, Jian; Young, Paul E.; Kenny, Joseph J.; Olsen, Henrik S.; Moore, Paul A.; **Wei, Ying-Fei**; Greene, John M.; Ruben, Steven M.; Liu, Ding; Crocker, Paul R. (USA). U.S. Pat. Appl. Publ. US 2003055231 A1 20030320, 453 pp., Cont.-in-part of U.S. Ser. No. 836,353. (English). CODEN: USXXCO. APPLICATION: US 2001-984130 20011029. PRIORITY: US 1998-PV105971 19981028; WO 1999-US25031 19991027; US 2000-PV198407 20000419; US 2000-PV243792 20001030; US 2001-836353 20010418.

AB The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 20 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:217994 Document No. 138:249901 Secreted protein HT5GJ57 of human and a cDNA encoding it with possible therapeutic uses. Ruben, Steven M.; Komatsoulis, George; Duan, Roxanne D.; Rosen, Craig A.; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David W.; Ebner, Reinhard; Olsen, Henrik; Brewer, Laurie A.; Florence, Kimberly A.; Young, Paul; Mucenski, Michael; Endress, Gregory A.; Soppet, Daniel R. (Human Genome Sciences, Inc., USA). U.S. US 6534631 B1 20030318, 325 pp., Cont.-in-part of Appl. No. PCT/US99/15849. (English). CODEN: USXXAM. APPLICATION: US 2000-482273 20000113. PRIORITY: US 1998-PV92956 19980715; US 1998-PV92922 19980715; US 1998-PV92921 19980715; WO 1999-US15849 19990714.

AB A novel human protein with features that indicate that it may be a secreted protein is identified and a cDNA encoding it is cloned. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L42 ANSWER 21 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:150550 Document No. 138:199986 Cloning and cDNA and deduced amino acid sequences of 207 human secreted proteins. Young, Paul; Greene, John M.; Ferrie, Ann M.; Ruben, Steven M.; Rosen, Craig A.; Hu, Jing-Shan; Olsen, Henrik S.; Ebner, Reinhard; Brewer, Laurie A.; Moore, Paul A.; **Shi, Yanggu**; Florence, Charles; Florence, Kimberly; Lafleur, David W.; Ni, Jian; Fan, Ping; **Wei, Ying-Fei**; Fischer, Carrie L.; Soppet, Daniel R.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla; Yu, Guo-Liang; Feng, Ping; Dillon, Patrick J.; Endress, Gregory A.; Carter, Kenneth C. (Human Genome Sciences, Inc., USA). U.S. US 6525174 B1 20030225, 156 pp., Cont.-in-part of Appl. No PCT/US98/11422. (English). CODEN: USXXAM. APPLICATION: US 1998-205258 19981204. PRIORITY: US 97-PV48885; 19970606; US 97-PV49375; 19970606; US 97-PV48881; 19970606; US 97-PV48880; 19970606; US 97-PV48896; 19970606; US 97-PV49020; 19970606; US 97-PV48876; 19970606; US 97-PV48895; 19970606; US 97-PV48884; 19970606; US 97-PV48894; 19970606; US 97-PV48971; 19970606; US 97-PV48964; 19970606; US 97-PV48882; 19970606; US 97-PV48899; 19970606; US 97-PV48893; 19970606; US 97-PV48900; 19970606; US 97-PV48901; 19970606; US 97-PV48892; 19970606; US 97-PV48915; 19970606; US 97-PV49019; 19970606.
AB The present invention relates to 207 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. In a preferred embodiment, the invention provides the cDNA and encoded amino acid sequences for a gene with sequence homol. with precerebellin of human, which is thought to be important in synaptic physiol. In Northern blots, precerebellin transcripts, with 4 distinct sizes, are abundant in cerebellum and infant brain, and present at either very low or undetectable levels in other brain areas and extra-neural structures. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 22 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:98032 Document No. 138:148752 Cloning and cDNA and deduced amino acid sequences of 125 human secreted proteins. Rosen, Craig A.; Feng, Ping; Ruben, Steven M.; Ebner, Reinhard; Olsen, Henrik S.; Ni, Jian; **Wei, Ying-Fei**; Soppet, Daniel R.; Moore, Paul A.; Kyaw, Hla; Lafleur, David W.; **Shi, Yanggu**; Janat, Fouad; Endress, Gregory A.; Carter, Kenneth C.; Birse, Charles E. (USA). U.S. Pat. Appl. Publ. US 2003028003 A1 20030206, 496 pp., Cont.-in-part of U.S. Ser. No. 818,683. (English). CODEN: USXXCO. APPLICATION: US 2001-974879 20011012. PRIORITY: US 1997-PV64911 19971107; US 1997-PV64912 19971107; US 1997-PV64983 19971107; US 1997-PV64900 19971107; US 1997-PV64988 19971107; US 1997-PV64987 19971107; US 1997-PV64908 19971107; US 1997-PV64984 19971107; US 1997-PV64985 19971107; US 1997-PV66094 19971117; US 1997-PV66100 19971117; US 1997-PV66089 19971117; US 1997-PV66095 19971117; US 1997-PV66090 19971117; WO 1998-US23435 19981104; US 1999-305736 19990505; US 2000-PV239893 20001013; US 2001-818683 20010328.
AB The present invention relates to 125 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 23 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2003:58220 Document No. 138:117676 Linear and cyclic melanocortin receptor-specific peptides, and therapeutic use. **Sharma, Shubh D.**; Shadiack, Annette M.; Yang, Wei; Rajpurohit, Ramesh (Palatin Technologies, Inc., USA). PCT Int. Appl. WO 2003006620 A2 20030123, 55 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US22196 20020711. PRIORITY: US 2001-PV304836 20010711.
AB Linear and cyclic peptides are provided which are specific to melanocortin receptors and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. The peptides of the invention may be used to treat e.g. erectile dysfunction and eating disorders.

L42 ANSWER 24 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:928144 Document No. 138:20531 Human ADAM metalloproteinase sequence homologs and cDNAs encoding them and antibodies to the proteins and their uses. Ruben, Steven M.; Ni, Jian; Hastings, Gregg A.; **Shi, Yanggu**; Wei, Ping (USA). U.S. Pat. Appl. Publ. US 2002182702 A1 20021205, 147 pp., Cont.-in-part of Appl. No. PCT/US00/14308. (English). CODEN: USXXCO. APPLICATION: US 2001-955504 20010919. PRIORITY: US 1999-PV136388 19990527; US 1999-PV142930 19990709; US 2000-PV178717 20000128; WO 2000-US14308 20000525; US 2000-PV234222 20000921; US 2000-712907 20001116.
AB CDNAs for human proteins with sequence homol. to ADAM metalloproteinases are identified and cloned. The cDNAs or the proteins may be useful in the treatment of disease (no data). Also provided are vectors, host cells, antibodies, and recombinant methods for producing human ADAM polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human ADAM polypeptides. Identification of the clones and anal. of tissue distribution of mRNAs by multiple tissue Northern blot are reported.

L42 ANSWER 25 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:889456 Document No. 138:1115 Cloning and cDNA and deduced amino acid sequences of 28 human secreted proteins. Ruben, Steven M.; Rosen, Craig A.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla; Fischer, Carrie L.; Li, Haodong; Soppet, Daniel R.; Gentz, Reiner L.; **Wei, Ying-fei**; Moore, Paul A.; Young, Paul E.; Greene, John M.; Ferrie, Ann M. (Human Genome Sciences, Inc., USA). U.S. Pat. Appl. Publ. US 2002172994 A1 20021121, 209 pp., Cont.-in-part of U.S. Ser. No. 152,060. (English). CODEN: USXXCO. APPLICATION: US 2001-852797 20010511. PRIORITY: US 1997-PV40762 19970314; US 1997-PV40710 19970314; US 1997-PV50934 19970530; US 1997-PV48100 19970530; US 1997-PV48357 19970530; US 1997-PV48189 19970530; US 1997-PV48970 19970606; US 1997-PV57765 19970905; US 1997-PV68368 19971219; WO 1998-US4858 19980312; US 1998-152060 19980911; US 2001-PV265583 20010202.
AB The present invention relates to 28 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 26 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:845503 Document No. 137:347552 Cloning and cDNA and deduced amino acid sequences of 94 human secreted proteins. Ruben, Steven M.; Ni, Jian; Rosen, Craig A.; **Wei, Ying-Fei**; Young, Paul; Florence, Kimberly; Soppet, Daniel R.; Brewer, Laurie A.; Endress, Gregory A.; Carter, Kenneth C.; Mucenski, Michael; Ebner, Reinhard; Lafleur, David W.; Olsen, Henrik; **Shi, Yanggu**; Moore, Paul A.; Komatsoulis, George (Human Genome Sciences, Inc., USA). U.S. US 6475753 B1 20021105, 157 pp., Cont.-in-part of Appl. No. PCT/US99/13418. (English). CODEN: USXXAM. APPLICATION: US 1999-461325 19991214. PRIORITY: US 1998-PV89507 19980616; US 1998-PV89508 19980616; US 1998-PV89509 19980616; US 1998-PV89510 19980616; US 1998-PV90112 19980622; US 1998-PV90113 19980622; WO 1999-US13418 19990615.
AB The present invention relates to 94 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins (Sequences for Seq ID:1-252 are not provided, in which only Seq ID 161 is claimed). Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 27 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:658737 Document No. 137:197519 Cloning of cDNAs for human serine proteases and therapeutic use thereof. Ni, Jian; **Shi, Yanggu**; Ruben, Steven M. (Human Genome Sciences, Inc., USA). U.S. Pat. Appl. Publ. US 2002119925 A1 20020829, 87 pp., Cont.-in-part of Appl. No. PCT/US00/12207. (English). CODEN: USXXCO. APPLICATION: US 2001-946633 20010906. PRIORITY: US 1999-PV133239 19990507; US 1999-PV147005 19990803; US 1999-PV152935 19990909; US 1999-PV162979 19991101; WO 2000-US12207 20000505.
AB The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

L42 ANSWER 28 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:637788 Document No. 137:179841 Identification of target-specific folding sites in peptides and proteins. **Sharma, Shubh D.**; **Shi, Yi-Qun** (Palatin Technologies, Inc., USA). PCT Int. Appl. WO 2002064734 A2 20020822, 165 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US50075 20011219. PRIORITY: US 2000-PV256842 20001219; US 2001-PV304835 20010711; US 2001-PV327835 20011004.
AB The invention provides methods for identification and determination of target-specific folding sites in peptides and proteins, including a method for determining a secondary structure binding to a target of interest within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between two adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence, which includes a min. of the residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion and two residues on the amino terminus side thereof, is complexed with a metal ion, thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The invention further provides methods to determine the specific sequence and local three-dimensional structure of that portion of peptides or proteins that bind to a receptor or target of interest, or mediate a biol. activity of interest and methods to determine the pharmacophore of receptors or targets of interest. The invention provides for defined pharmacophores or receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.

L42 ANSWER 29 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:637480 Document No. 137:190724 Melanocortin metallopeptides for treatment of sexual dysfunction. **Sharma, Shubh D.**; **Shi, Yi-qun**; Yang, Wei; **Cai, Hui-zhi**; Shadiack, Annette (Palatin Technologies, Inc., USA). PCT Int. Appl. WO 2002064091 A2 20020822, 58 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US4431 20020213. PRIORITY: US 2001-PV268591 20010213.
AB Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.

L42 ANSWER 30 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:555624 Document No. 137:104821 Human nucleic acids encoding 50 human secreted proteins and their diagnostic and therapeutic uses. Moore, Paul A.; Ruben, Steven M.; Lafleur, David W.; **Shi, Yanggu**; Rosen, Craig A.; Olsen, Henrik; Ebner, Reinhard; Brewer, Laurie A. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2002057420 A2 20020725, 785 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US1109 20020117. PRIORITY: US 2001-PV262066 20010118.
AB The present invention relates to 50 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L42 ANSWER 31 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:484867 Document No. 137:58593 Protein and cDNA sequences of a human cornichon-like protein, its expression vector, antibody, diagnosis and therapeutic uses thereof. Ruben, Steven M.; Rosen, Craig A.; Fan, Ping; Kyaw, Hla; **Wei, Ying-fei** (Human Genome Sciences, Inc., USA). U.S. US 6410709 B1 20020625, 98 pp., Cont.-in-part of Appl. No. PCT/US98/17709. (English). CODEN: USXXAM. APPLICATION: US 1999-257179 19990225. PRIORITY: US 1997-PV56270 19970829; US 1997-PV56271 19970829; US 1997-PV56247 19970829; US 1997-PV56073 19970829; WO 1998-US17709 19980827.
AB The present invention provides protein and cDNA sequences of a novel human secreted proteins, cornichon-like protein, and methods related to its applications. Specifically, the invention relates to expression vector encoding the protein, host cells transfected with the gene, antibodies, recombinant methods for producing human secreted proteins, and gene knockout animals. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

L42 ANSWER 32 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:466698 Document No. 137:42654 Cloning and cDNA and deduced amino acid sequences of 28 human secreted proteins. Ruben, Steven M.; Rosen, Craig A.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla; Fischer, Carrie L.; Li, Haodong; Soppet, Daniel R.; Gentz, Reiner L.; **Wei, Ying-fei**; Moore, Paul A.; Young, Paul E.; Greene, John M.; Ferrie, Ann M. (USA). U.S. Pat. Appl. Publ. US 2002077287 A1 20020620, 209 pp., Cont.-in-part of U.S. Ser. No. 152,060. (English). CODEN: USXXCO. APPLICATION: US 2001-852659 20010511. PRIORITY: US 1998-152060 19980911.
AB The present invention relates to 28 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 33 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:466616 Document No. 137:42653 Cloning and cDNA and deduced amino acid sequences of 28 human secreted proteins. Ruben, Steven M.; Rosen, Craig A.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla; Fischer, Carrie L.; Li, Haodong; Soppet, Daniel R.; Gentz, Reiner L.; **Wei, Ying-fei**; Moore, Paul A.; Young, Paul E.; Greene, John M.; Ferrie, Ann M. (USA). U.S. Pat. Appl. Publ. US 2002076756 A1 20020620, 209 pp., Cont.-in-part of U.S. Ser. No. 152,060. (English). CODEN: USXXCO. APPLICATION: US 2001-853161 20010511. PRIORITY: WO 1998-US4858 19980312; US 1998-152060 19980911; US 2001-PV265583 20010202.
AB The present invention relates to 28 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 34 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:256425 Document No. 136:258373 Cloning and cDNA and deduced amino acid sequences of 71 human secreted proteins. Ruben, Steven M.; Komatsoulis, George; Duan, D. Roxanne; Rosen, Craig A.; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David W.; Olsen, Henrik; Brewer, Laurie A.; Florence, Kimberly A.; Young, Paul E.; Soppet, Daniel R.; Endress, Gregory A.; Mucenski, Michael; Ebner, Reinhard (Human Genome Sciences, Inc., USA).
PCT Int. Appl. WO 2002026931 A2 20020404, 1478 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US29871 20010924. PRIORITY: US 2000-PV234925 20000925; WO 2001-US911 20010112.
AB The present invention relates to 71 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 35 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:172435 Document No. 136:211966 Cloning and cDNA and deduced amino acid sequences of 26 human secreted proteins. Ruben, Steven M.; Birse, Charles E.; Duan, Roxanne D.; Soppet, Daniel R.; Rosen, Craig A.; **Shi, Yanggu**; Lafleur, David W.; Olsen, Henrik; Ebner, Reinhard; Florence, Kimberly A.; Ni, Jian; Young, Paul (USA). U.S. Pat. Appl. Publ. US 2002028449 A1 20020307, 263 pp., Cont.-in-part of Appl. No. PCT/US00/15187. (English). CODEN: USXXCO. APPLICATION: US 2000-726643 20001201. PRIORITY: US 1999-PV137725 19990607; WO 2000-US15187 20000602.
AB The present invention relates to 26 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 36 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:171947 Document No. 136:211952 Cloning and cDNA and deduced amino acid sequences of 18 human secreted proteins. Rosen, Craig A.; Komatsoulis, George A.; Baker, Kevin P.; Birse, Charles E.; Soppet, Daniel R.; Olsen, Henrik S.; Moore, Paul A.; Wei, Ping; Ebner, Reinhard; Duan, D. Roxanne; **Shi, Yanggu**; Choi, Gil H.; Piscella, Michele; Ni, Jian (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2002018435 A1 20020307, 504 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US1567 20010117. PRIORITY: US 2000-PV228084 20000828.
AB The present invention relates to 18 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 37 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2002:157966 Document No. 136:179059 Cloning and cDNA and deduced amino acid sequences of 11 human secreted proteins. Rosen, Craig A.; Komatsoulis, George A.; Baker, Kevin P.; Birse, Charles E.; Soppet, Daniel R.; Olsen, Henrik S.; Moore, Paul A.; Wei, Ping; Ebner, Reinhard; Duan, D. Roxanne; **Shi, Yanggu**; Choi, Gil H.; Fiscella, Michele; Ni, Jian (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2002016576 A1 20020228, 462 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US1396 20010117. PRIORITY: US 2000-PV226280 20000818; US 2000-PV256968 20001221.
AB The present invention relates to 11 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 38 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:935768 Document No. 136:65973 Putative human serine proteases and cDNAs and their use in disease diagnosis and treatment. Ruben, Steven M.; Ni, Jian; **Shi, Yanggu** (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001098476 A1 20011227, 263 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US16848 20000620.
AB The present invention relates to putative novel human serine proteases and isolated cDNAs containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to the proteins. Thus, 4 human cDNAs were isolated. The translation product of the first shared sequence homol. with MEGF-6 from Rattus norvegicus as well as matrilin-2. The gene for this protein was strongly expressed in umbilical vein and aortic endothelial cells, heart, and thymus. The proteins encoded by the second and third cDNAs exhibited sequence homol. with a human multimeric protein containing a serine proteinase domain as well as hepsin. One of these genes was expressed primarily in healing abdomen wound tissue; the other was expressed primarily in prostate and uterus. The fourth protein showed sequence homol. with human plasma kallikrein and its gene was expressed primarily in fetal liver and spleen.

L42 ANSWER 39 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:636184 Document No. 135:206481 Two hundred seven cDNAs encoding human proteins with signal peptides. Ni, Jian; Ebner, Reinhard; Lafleur, David W.; Moore, Paul A.; Olsen, Henrik S.; Rosen, Craig A.; Ruben, Steven M.; Soppet, Daniel R.; Young, Paul E.; **Shi, Yanggu**; Florence, Kimberly A.; **Wei, Ying-fei**; Florence, Charles; Hu, Jing-shan; Li, Yi; Kyaw, Hla; Fischer, Carrie L.; Ferrie, Ann M.; Fan, Ping; Feng, Ping; Endress, Gregory A.; Dillon, Patrick J.; Carter, Kennith C.; Brewer, Laurie A.; Yu, Guo-liang; Zeng, Zhizhen; Greene, John M. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001062891 A2 20010830, 1533 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US5614 20010221. PRIORITY: US 2000-PV184836 20000224; US 2000-PV193170 20000329.
AB The sequences of 207 cDNAs encoding human secreted proteins are disclosed. Antigenic epitope sites, putative chromosomal locations, tissue expression, and biol. activity assays are also provided. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.

L42 ANSWER 40 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:545736 Document No. 135:148242 Human polypeptides and their encoding cDNA sequences and antibodies. Ruben, Steven M.; **Shi, Yanggu** (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001053343 A1 20010726, 339 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US1436 20010117. PRIORITY: US 2000-PV176307 20000118.
AB The present invention relates to 4 novel human human polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. The cDNA clone HE8QT72 encodes a protein showing sequence homol. with murine semaphorin VIa, and is expressed in human 8-wk-old embryonic tissue and frontal cortex tissue. Clone HSIDD62 encodes a protein homologous to human atrial natriuretic polypeptide binding protein and is expressed in small intestine, colon tumor, and ovarian tumor tissues. The third clone (HNALE36) encodes a protein with homol. to human MAL protein and is expressed in a variety of cancerous tissues, including endometrial tumor, ovarian cancer, lung cancer, and breast cancer tissues. Finally, clone HCEVB07 encodes a protein homologous to Torsin A protein and is expressed in human cerebellum tissue. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human human polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human human polypeptides.

L42 ANSWER 41 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:526089 Document No. 135:117952 Cloning and cDNA and deduced amino acid sequences of 71 human secreted proteins. Ruben, Steven M.; Komatsoulis, George A.; Duan, D. Roxanne; Rosen, Craig A.; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David W.; Olsen, Henrik S.; Brewer, Laurie A.; Florence, Kimberly A.; Young, Paul E.; Soppet, Daniel R.; Endress, Gregory A.; Muscenski, Michael; Ebner, Reinhard (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001051504 A1 20010719, 864 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US911 20010112. PRIORITY: US 2000-482273 20000113.
AB The present invention relates to 71 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities (no data) of the secreted proteins.

L42 ANSWER 42 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:510831 Correction of: 1998:640255 Document No. 135:56941 Correction of: 129:240888 Cloning and cDNA and deduced amino acid sequences of 186 human secreted proteins. Ruben, Steven M.; Rosen, Craig A.; Fischer, Carrie L.; Soppet, Daniel R.; Carter, Kenneth C.; Bednarik, Daniel P.; Endress, Gregory A.; Yu, Guo-liang; Ni, Jian; Feng, Ping; Young, Pdaul E.; Greene, John M.; Gerrie, Ann M.; Duan, Roxanne; Hu, Jing-Shan; Florence, Kimberly A.; Olsen, Henrik S.; Ebner, Reinhard; Brewer, Laurie A.; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David W.; Li, Yi; Zeng, Zhizhen; Kyaw, Hla (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9839448 A2 19980911, 748 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US4493 19980306. PRIORITY: US 97-PV40162; 19970307; US 97-PV40333; 19970307; US 97-PV38621; 19970307; US 97-PV40161; 19970307; US 97-PV40626; 19970307; US 97-PV40334; 19970307; US 97-PV40336; 19970307; US 97-PV40163; 19970307; US 97-PV43580; 19970411; US 97-PV43568; 19970411; US 97-PV43314; 19970411; US 97-PV43569; 19970411; US 97-PV43311; 19970411; US 97-PV43671; 19970411; US 97-PV43674; 19970411; US 97-PV43669; 19970411; US 97-PV43312; 19970411; US 97-PV43313; 19970411; US 97-PV43672; 19970411; US 97-PV43315; 19970411.
AB The present invention relates to 186 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 43 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:360142 Document No. 134:362259 Cloning and cDNA and deduced amino acid sequences of 22 human secreted proteins. Soppet, Daniel R.; Komatsoulis, George; **Shi, Yanggu**; Olsen, Henrik S.; Ruben, Steven M. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001034767 A2 20010517, 540 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US30036 20001101. PRIORITY: US 1999-PV163576 19991105; US 2000-PV221366 20000727.
AB The present invention relates to 22 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 44 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:360034 Document No. 135:1252 Cloning and cDNA and deduced amino acid sequences of 24 human secreted proteins. Ruben, Steven M.; Komatsoulis, George A.; Soppet, Daniel R.; **Shi, Yang-Gu** (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001034643 A1 20010517, 532 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US30629 20001108. PRIORITY: US 1999-PV164825 19991112; US 2000-PV222904 20000803.
AB The present invention relates to 24 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 45 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:338545 Document No. 134:348989 Cloning and cDNA and deduced amino acid sequences of 25 human secreted proteins. Ruben, Steven M.; Komatsoulis, George A.; **Shi, Yang-Gu**; Olsen, Henrik S.; Soppet, Daniel R. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001032676 A1 20010510, 546 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US29365 20001025. PRIORITY: US 1999-PV162237 19991029; US 2000-PV219666 20000721.
AB The present invention relates to 25 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 46 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:185773 Document No. 134:203478 Cloning and cDNA and deduced amino acid sequences of 52 human secreted proteins. Ni, Jian; Baker, Kevin P.; Birse, Charles E.; Fiscella, Michele; Komatsoulis, George A.; Rosen, Craig A.; Soppet, Daniel R.; Young, Paul E.; Ebner, Reinhard; Duan, D. Roxanne; Olsen, Henrik S.; Lafleur, David W.; Moore, Paul A.; **Shi, Yanggu**; **Wei, Ying-fei**; Florence, Kimberly A. (Human Genome Sciences, Inc., USA; et al.). PCT Int. Appl. WO 2001018022 A1 20010315, 607 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US24008 20000831. PRIORITY: US 1999-PV152317 19990903; US 1999-PV152315 19990903.
AB The present invention relates to 52 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 47 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:78402 Document No. 134:126846 Cloning and cDNA and deduced amino acid sequences of 29 human secreted proteins. Rosen, Craig A.; Ruben, Steven M.; Ebner, Reinhard; Duan, Roxanne D.; Ni, Jian; Soppet, Daniel R.; Moore, Paul A.; **Shi, Yang-Gu**; Lafleur, David W.; Olsen, Henrik S.; Birse, Charles E.; Komatsoulis, Georges A. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2001007459 A1 20010201, 601 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US19735 20000720. PRIORITY: US 1999-PV145220 19990723.
AB The present invention relates to 29 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities (no data) of the secreted proteins.

L42 ANSWER 48 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2001:64594 Document No. 134:246925 Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. **Sharma, Sudhir**; Verma, Indu; Khuller, G. K. (Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, 160 012, India). Antimicrobial Agents and Chemotherapy, 45(2), 639-640 (English) 2001. CODEN: AMACCQ. ISSN: 0066-4804. Publisher: American Society for Microbiology.
AB The therapeutic efficacy of human neutrophil peptide 1 (HNP-1) against exptl. tuberculosis in mice on the basis of nos. of CFU has been examined Mice infected with 1.5 + 104 CFU of Mycobacterium tuberculosis H37Rv and treated with different doses of HNP-1 injected s.c. exhibited significant clearance of bacilli from lungs, livers, and spleens. There were time- and dose-dependent decreases in the bacillary load in lungs, livers, and spleens of the HNP-1-treated animals compared to that in controls (untreated animals). These observations strongly suggest the therapeutic activity of HNP-1 against tuberculosis.

L42 ANSWER 49 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:881360 Document No. 134:37960 Cloning and cDNA and deduced amino acid sequences of 26 human secreted proteins. Ruben, Steven M.; Birse, Charles
E.; Duan, Roxanne D.; Soppet, Daniel R.; Rosen, Craig A.; **Shi, Yanggu**; Lafleur, David W.; Olsen, Henrik S.; Ebner, Reinhard; Florence, Kimberly A.; Ni, Jian; Young, Paul E. (Human Genome Sciences, Inc., USA; et al.). PCT Int. Appl. WO 2000075375 A1 20001214, 530 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,
CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US15187 20000602. PRIORITY: US 1999-PV137725 19990607.
AB The present invention relates to 26 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding
such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host
cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further
relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 50 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:842859 Document No. 134:126122 Discovery that deltorphin II derivatives
are potent melanotropins, putatively active at the Xenopus melanocortin-1 receptor. Hruby, V. J.; Han, G.; Quillan, M. J.; Sadee, W.; **Sharma, S.** (Department of Chemistry, University of Arizona, Tucson, AZ, 85721-0041, USA). Peptides: Biology and Chemistry, Proceedings of the Chinese Peptide Symposium, 5th, Lanzhou, China, July 14-17, 1998, Meeting Date 1998, 172-174. Editor(s): Hu, Xiao-Yu; Wang, Rui; Tam, James P. Kluwer Academic Publishers: Dordrecht, Neth. (English) 2000. CODEN: 69AQX6.
AB The authors studied the relation between the structures of 6 deltorphin II
analogs and their reactivity with Xenopus melanocortin 1 receptors. Extending the N-terminus of deltorphin II by arginine produced a relative potent MSH-like compound Extending the N-terminus with lysine produced a somewhat weaker compound, whereas activity was markedly decreased when the
mol. was restricted by substitutions with D-penicillamine or by formation of lactam bridges.

L42 ANSWER 51 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:814501 Document No. 133:359812 Cloning and cDNA and deduced amino acid sequences of nine human serine proteases. Ruben, Steven M.; **Shi, Yanggu**; Young, Paul E.; Ni, Jian (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000068247 A2 20001116, 289 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US12207 20000505. PRIORITY: US 1999-PV133239 19990507; US 1999-PV135163 19990520; US 1999-PV147005 19990803; US 1999-PV152935 19990909; US 1999-PV162979 19991101.
AB The present invention relates to 9 novel human serine protease proteins and isolated nucleic acids containing the coding regions of the genes encoding
such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the serine proteases proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host
cells, antibodies, and recombinant methods for producing human serine protease proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for
diagnosing and treating disorders related to these novel human serine proteases. High-throughput screening assays are also provided for various
putative activities of the serine protease proteins.

L42 ANSWER 52 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:742268 Document No. 133:292004 Cloning of human bone morphogenic proteins BMPs and their therapeutic use. Ruben, Steven M.; Ni, Jian; Komatsoulis, George; Rosen, Craig A.; **Shi, Yanggu** (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000061774 A2 20001019, 291 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,
CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US9028 20000406. PRIORITY: US 1999-PV128701 19990409; US 1999-PV130693 19990423; US 1999-PV131672 19990429; US 1999-PV138632 19990611; US 1999-PV147020 19990803; US 1999-PV152933 19990909.
AB The present invention relates to novel human BMP polypeptides and isolated
nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

L42 ANSWER 53 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:742131 Document No. 133:291991 Cloning and cDNA and deduced amino acid sequences of 62 human secreted proteins. Ruben, Steven M.; Ni, Jian; Komatsoulis, George A.; Rosen, Craig A.; Soppet, Daniel R.; **Shi, Yanggu**; Lafleur, David W.; Olsen, Henrik S.; Ebner, Reinhard; Florence, Kimberly A.; Moore, Paul A.; Birse, Charles E.; Young, Paul E. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000061623 A1 20001019, 716 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US8979 20000406. PRIORITY: US 1999-PV128693 19990409; US 1999-PV130991 19990426.
AB The present invention relates to 62 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 54 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:666922 Document No. 133:248079 Cloning and cDNA and deduced amino acid sequences of 27 human secreted proteins. Ruben, Steven M.; Ni, Jian; Ebner, Reinhard; Rosen, Craig A.; **Shi, Yanggu**; Birse, Charles; Florence, Kimberly; Komatsoulis, George; Lafleur, David W.; Moore, Paul A.; Olsen, Henrik S.; Young, Paul E. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000055371 A1 20000921, 453 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US6783 20000316. PRIORITY: US 1999-PV125055 19990318.
AB The present invention relates to 27 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 55 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:421158 Document No. 133:54549 Cloning and cDNA and deduced amino acid sequences of 47 human secreted proteins. Ruben, Steven M.; Ebner, Reinhard; Rosen, Craig A.; Endress, Gregory A.; Soppet, Daniel R.; Ni, Jian; Duan, D. Roxanne; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David W.; Olsen, Henrik S.; Florence, Kimberly (Human Genome Sciences, Inc., USA; et al.). PCT Int. Appl. WO 2000035937 A1 20000622, 562 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US29950 19991216. PRIORITY: US 1998-PV112809 19981217; US 1998-PV113006 19981218.
AB The present invention relates to 47 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 56 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:351552 Document No. 133:13420 Cloning and cDNA and deduced amino acid sequences of 12 human secreted proteins. Ni, Jian; Ruben, Steven M.; Olsen, Henrik S.; Young, Paul E.; Kenny, Joseph J.; Moore, Paul A.; **Wei, Ying-Fei**; Greene, John M. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000029435 A1 20000525, 803 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US25031 19991027. PRIORITY: US 1998-PV105971 19981028.
AB The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 57 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:210198 Document No. 132:218021 Cloning and cDNA and deduced amino acid sequences of 31 human secreted proteins. Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.; **Shi, Yanggu**; Lafleur, David W.; Young, Paul E.; Ni, Jian; Komatsoulis, George; Endress, Gregory A.; Soppet, Daniel R. (Human Genome Sciences, Inc., USA; et al.). PCT Int. Appl. WO 2000017222 A1 20000330, 416 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US22012 19990922. PRIORITY: US 1998-101546 19980923; US 1998-102895 19981002.

AB The present invention relates to 31 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 58 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:145032 Document No. 132:206925 Recombinant multivalent malarial vaccine against Plasmodium falciparum. Lal, Altaf A.; **Shi, Ya Ping**; Hasnain, Seyed E. (United States Dept. of Health and Human Services, USA; National Institute of Immunology). PCT Int. Appl. WO 2000011179 A1 20000302, 52 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US18869 19990819. PRIORITY: US 1998-97703 19980821.

AB A recombinant protein is provided which comprises peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum. The protein is useful as a reagent and, when combined with a pharmaceutically-acceptable vehicle or carrier, is useful as a vaccine against the malarial parasite Plasmodium falciparum . A genetic construct used to produce this recombinant protein vaccine is also described. In addition, antibodies to this recombinant protein are provided which are useful for the detection and measurement of peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum. Thus, antigen CDC/NIIMALVAC-1 was prepared using a baculovirus/Sf21 cell system and tested as a vaccine. The CDC/NIIMALVAC-1 antigen contains epitopes from the blood stage (MSP-1, MSP-2, AMA-1, EBA-175, and RAP-1), the liver stage (LSA-1), the sporozoite stage (CSP and SSP-2), and the gametocyte stage (Pfg27).

L42 ANSWER 59 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:144892 Document No. 132:190523 Cloning and cDNA and deduced amino acid sequences of 49 human secreted proteins. Moore, Paul A.; Ruben, Steven M.; Olsen, Henrik S.; **Shi, Yang-Gu**; Rosen, Craig A.; Florence, Kimberly A.; Soppet, Daniel R.; Lafleur, David W.; Endress, Gregory A.; Ebner, Reinhard; Komatsoulis, George; Duan, Roxanne D. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000011014 A1 20000302, 416 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US19330 19990824. PRIORITY: US 1998-97917 19980825; US 1998-98634 19980831.

AB The present invention relates to 49 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 60 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:98720 Document No. 132:147628 Cloning and cDNA and deduced amino acid sequences of 98 human secreted proteins. Komatsoulis, George A.; Rosen, Craig A.; Ruben, Steven M.; Duan, Roxanne; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David; **Wei, Ying-Fei**; Ni, Jian; Florence, Kimberly A.; Young, Paul E.; Brewer, Laurie A.; Soppet, Daniel R.; Endress, Gregory A.; Ebner, Reinhard; Olsen, Henrik S.; Mucenski, Michael (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 2000006698 A1 20000210, 634 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CP, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US17130 19990729. PRIORITY: US 1998-94657 19980730; US 1998-95486 19980805; US 1998-95455 19980806; US 1998-95454 19980806; US 1998-96319 19980812.

AB The present invention relates to 98 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 61 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
2000:68550 Document No. 132:103779 Cloning and cDNA and deduced amino acid sequences of 71 human secreted proteins. Ruben, Steven M.; Komatsoulis, George; Duan, Roxanne D.; Rosen, Craig A.; Moore, Paul A.; **Shi, Yang-Gu**; Lafleur, David W.; Ebner, Reinhard; Olsen, Henrik S.; Brewer, Laurie A.; Florence, Kimberly A.; Young, Paul E.; Mucenski, Michael; Endress, Gregory A.; Soppet, Daniel R. (Human Genome Sciences, Inc., USA; et al.). PCT Int. Appl. WO 2000004140 A1 20000127, 494 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US15849 19990714. PRIORITY: US 1998-92921 19980715; US 1998-92922 19980715; US 1998-92956 19980715.
AB The present invention relates to 71 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 62 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:811359 Document No. 132:45843 Cloning and cDNA and deduced amino acid sequences of 94 human secreted proteins. Ruben, Steven M.; Ni, Jian; Rosen, Craig A.; **Wei, Ying-Fei**; Young, Paul E.; Florence, Kimberly A.; Soppet, Daniel R.; Brewer, Laurie A.; Endress, Gregory A.; Carter, Kenneth C.; Mucenski, Michael; Ebner, Reinhard; Lafleur, David W.; Olsen, Henrik S.; **Shi, Yanggu**; Moore, Paul A.; Komatsoulis, George (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9966041 A1 19991223, 588 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US13418 19990615. PRIORITY: US 1998-89509 19980616; US 1998-89510 19980616; US 1998-89508 19980616; US 1998-89507 19980616; US 1998-90112 19980622; US 1998-90113 19980622.
AB The present invention relates to 94 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 63 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:736899 Document No. 132:956 Cloning and cDNA and deduced amino acid sequences of 97 human secreted proteins. Ruben, Steven M.; Florence, Kimberly; Ni, Jian; Rosen, Craig A.; Carter, Kenneth C.; Moore, Paul A.; Olsen, Henrik S.; **Shi, Yang-Gu**; Young, Paul E.; Wei, Fing-Fei; Brewer, Laurie A.; Soppet, Daniel R.; Lafleur, David W.; Endress, Gregory A.; Ebner, Reinhard (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9958660 A1 19991118, 475 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US9847 19990506. PRIORITY: US 1998-85093 19980512; US 1998-85094 19980512; US 1998-85105 19980512; US 1998-85180 19980512; US 1998-85927 19980518; US 1998-85906 19980518; US 1998-85924 19980518; US 1998-85922 19980518; US 1998-85923 19980518; US 1998-85921 19980518; US 1998-85925 19980518; US 1998-85928 19980518; US 1998-85920 19980518.
AB The present invention relates to 97 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 64 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:613933 Document No. 131:224482 Cloning and cDNA and deduced amino acid sequences of 95 human secreted proteins. Ruben, Steven M.; Ni, Jian; Rosen, Craig A.; Yu, Guo-Liang; Young, Paul E.; Feng, Ping; Soppet, Daniel R.; **Wei, Ying-Fei**; Endress, Gregory A.; Duan, Roxanne D.; Kyaw, Hla; Ebner, Reinhard; Lafleur, David W.; Olsen, Henrik S.; **Shi, Yanggu**; Moore, Paul A. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9947540 A1 19990923, 485 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US5804 19990318. PRIORITY: US 1998-PV78566 19980319; US 1998-PV78576 19980319; US 1998-PV78573 19980319; US 1998-PV78574 19980319; US 1998-PV78579 19980319; US 1998-PV78578 19980319; US 1998-PV78581 19980319; US 1998-PV78577 19980319; US 1998-PV78563 19980319; US 1998-PV80314 19980401; US 1998-PV80312 19980401; US 1998-PV80313 19980401.
AB The present invention relates to 95 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 65 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:328001 Document No. 131:127510 Biochemical interaction of human neutrophil peptide-1 with Mycobacterium tuberculosis H37Ra. **Sharma, Sudhir**; Verma, Indu; Khuller, G. K. (Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India). Archives of Microbiology, 171(5), 338-342 (English) 1999.
CODEN: AMICCW. ISSN: 0302-8933. Publisher: Springer-Verlag.
AB The biochem. mechanism of action of human neutrophil peptide-1 (HNP-1) against Mycobacterium tuberculosis H37Ra was studied. Mycobacteria grown in the presence of a subinhibitory concentration (IC50) of HNP-1 showed a significant decrease in the biosynthesis of vital macromols., as shown by the incorporation of various radiolabeled precursors. Mycobacterial cells grown in the presence of HNP-1 exhibited surface changes, as was evident from the increased number of binding sites for L-anilinonaphthalene 8-sulfonate. Permeability studies carried out with spheroplasts showed a significantly high permeability to a fluorescent probe, N-Ph naphthylamine, in the presence of HNP-1. Significant changes in the cell wall and cell membrane were observed when HNP-1-grown cells were analyzed by transmission electron microscopy. Our results suggest the mycobacterial cell wall/membrane to be the major target(s) of HNP-1.

L42 ANSWER 66 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:317174 Document No. 130:333752 Cloning and cDNA and deduced amino acid sequences of 148 human secreted proteins. Feng, Ping; Rosen, Craig A.; Ruben, Steven M.; Ni, Jian; **Wei, Ying-fei**; Soppet, Daniel R.; Moore, Paul A.; Kayw, Hla; Lafleur, David W.; Olsen, Henrik S.; Brewer, Laurie A.; **Shi, Yanggu**; Ebner, Reinhard; Young, Paul; Greene, John M.; Florence, Kimberly A.; Florence, Charles; Duan, D. Roxanne; Janat, Fouad; Endress, Gregory A.; Carter, Kenneth C. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9922243 A1 19990506, 545 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US22376 19981023. PRIORITY: US 1997-63099 19971024; US 1997-63088 19971024; US 1997-63100 19971024; US 1997-63387 19971024; US 1997-63148 19971024; US 1997-63386 19971024; US 1997-62784 19971024; US 1997-63091 19971024; US 1997-63090 19971024; US 1997-63089 19971024; US 1997-63092 19971024; US 1997-63111 19971024; US 1997-63101 19971024; US 1997-63109 19971024; US 1997-63110 19971024.
AB The present invention relates to 148 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 67 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:184159 Document No. 130:233265 Cloning and cDNA and deduced amino acid sequences of 50 human secreted proteins. Moore, Paul A.; Ruben, Steven M.; Lafleur, David W.; **Shi, Yang-Gu**; Rosen, Craig A.; Olsen, Henrik S.; Ebner, Reinhard; Brewer, Laurie A. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9911293 A1 19990311, 217 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US18360 19980903. PRIORITY: US 1997-57626 19970905; US 1997-57663 19970905; US 1997-57669 19970905; US 1997-58667 19970912; US 1997-58974 19970912; US 1997-58973 19970912; US 1997-58666 19970912.
AB The present invention relates to 50 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 68 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:166629 Document No. 130:192793 Cloning and cDNA and deduced amino acid sequences of 29 human secreted proteins. Ruben, Steven M.; Rosen, Craig A.; Fan, Ping; Kyaw, Hla; **Wei, Ying Fei** (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9910363 A1 19990304, 170 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US17709 19980827. PRIORITY: US 1997-56073 19970829; US 1997-56271 19970829; US 1997-56270 19970829; US 1997-56247 19970829.
AB The present invention relates to 29 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 69 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:150918 Document No. 130:310369 Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. **Shi, Ya Ping**; Hasnain, Seyed E.; Sacci, John B.; Holloway, Brian P.; Fujioka, Hisashi; Kumar, Nirbhay; Wohlhueter, Robert; Hoffman, Stephen L.; Collins, William E.; Lal, Altaf A. (Division of Parasitic Diseases, Centers for Disease Control and Prevention, National Centers for Infectious Diseases, Atlanta, GA, 30333, USA). Proceedings of the National Academy of Sciences of the United States of America, 96(4), 1615-1620 (English) 1999. CODEN: PNASA6. ISSN: 0027-8424. Publisher: National Academy of Sciences.
AB Compared with a single-stage antigen-based vaccine, a multistage and multivalent Plasmodium falciparum vaccine would be more efficacious by inducing "multiple layers" of immunity. The authors have constructed a synthetic gene that encodes for 12 B cell, 6 T cell proliferative, and 3 cytotoxic T lymphocyte epitopes derived from 9 stage-specific P. falciparum antigens corresponding to the sporozoite, liver, erythrocytic asexual, and sexual stages. The gene was expressed in the baculovirus system, and a 41-kDa antigen, termed CDC/NIIMALVAC-1, was purified. Immunization in rabbits with the purified protein in the presence of different adjuvants generated antibody responses that recognized vaccine antigen, linear peptides contained in the vaccine, and all stages of P. falciparum. In vitro assays of protection revealed that the vaccine-elicited antibodies strongly inhibited sporozoite invasion of hepatoma cells and growth of blood-stage parasites in the presence of monocytes. These observations demonstrate that a multicomponent, multistage malaria vaccine can induce immune responses that inhibit parasite development of a multiple stages. The rationale and approach used in the development of a multicomponent P. falciparum vaccine will be useful in the development of a multispecies human malaria vaccine and vaccines against other infectious diseases.

L42 ANSWER 70 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:139950 Document No. 130:192784 Cloning and cDNA and deduced amino acid sequences of 70 human secreted proteins. Ruben, Steven M.; Young, Paul E.; Brewer, Laurie A.; Ebner, Reinhard; Olsen, Henrik S.; Florence, Kimberly A.; Rosen, Craig A.; Duan, Roxanne; Moore, Paul A.; **Shi, Yanggu**; Lafleur, David W.; Florence, Charles; Soppet, Daniel R.; Endress, Gregory A.; Feng, Ping; Komatsoulis, George A. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9909155 A1 19990225, 280 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US17044 19980818. PRIORITY: US 1997-56555 19970819; US 1997-56556 19970819; US 1997-56535 19970819; US 1997-56629 19970819; US 1997-56369 19970819; US 1997-56628 19970819; US 1997-56728 19970819; US 1997-56368 19970819; US 1997-56726 19970819; US 1998-89510 19980616; US 1998-92956 19980715.
AB The present invention relates to 70 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 71 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:71999 Document No. 130:106059 Cloning and cDNA and deduced amino acid sequences of 123 human secreted proteins. Fischer, Carrie L.; Rosen, Craig A.; Soppet, Daniel R.; Ruben, Steven M.; Kyaw, Hla; Li, Yi; Zeng, Zhizhen; Lafleur, David W.; Moore, Paul A.; **Shi, Yanggu**; Olsen, Henrik S.; Ebner, Reinhard; Brewer, Laurie A. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9902546 A1 19990121, 464 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US13684 19980707. PRIORITY: US 1997-51926 19970708; US 1997-51929 19970708; US 1997-52793 19970708; US 1997-51925 19970708; US 1997-51931 19970708; US 1997-51932 19970708; US 1997-52803 19970708; US 1997-52732 19970708; US 1997-51916 19970708; US 1997-51930 19970708; US 1997-51918 19970708; US 1997-51920 19970708; US 1997-51919 19970708; US 1997-51928 19970708; US 1997-52795 19970708; US 1997-52733 19970708; US 1997-55948 19970818; US 1997-55722 19970818; US 1997-55723 19970818; US 1997-55949 19970818.
AB The present invention relates to 123 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 72 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1999:34934 Document No. 130:109213 Cloning and cDNA sequence of human cardiotrophin-like cytokine CLC. **Shi, Yanggu**; Ruben, Steven M. (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9900415 A1 19990107, 103 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US13129 19980629. PRIORITY: US 1997-51311 19970630.
AB The present invention relates to a novel cardiotrophin-like cytokine (CLC) protein which is a member of the interleukin-6 cytokine family. In particular, cDNA mols. are provided encoding the human CLC protein comprising 225 amino acids, including a 27-residue signal moiety. The CLC protein shares sequence homol. with rat cardiotrophin-1, human cardiotrophin, LIF, and CNTF. Signal transduction pathways involving the GAS (γ-activation site) and SRE (steroid-response element) elements are activated in TF-1 and M1 cells in response to CLC stimulation; CLC also inhibits M1 cell proliferation and reduces cardiac myocyte hypertrophy. CLC polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CLC activity. Also provided are diagnostic methods for detecting cardiac and immune system-related disorders and therapeutic methods for treating cardiac and immune system-related disorders.

L42 ANSWER 73 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1998:806571 Document No. 130:62037 Cloning and cDNA and deduced amino acid sequences of 207 human secreted proteins. Young, Paul; Greene, John M.; Ferrie, Ann M.; Ruben, Steven M.; Rosen, Craig A.; Hu, Jing-shan; Olsen, Henrik S.; Ebner, Reinhard; Brewer, Laurie A.; Moore, Paul A.; Shi, Yanggu; Florence, Charles; Florence, Kimberly; Lafleur, David W.; Ni, Jian (Human Genome Sciences, Inc., USA). PCT Int. Appl. WO 9854963 A2 19981210, 772 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US11422 19980604. PRIORITY: US 1997-48915 19970606; US 1997-48882 19970606; US 1997-48892 19970606; US 1997-48901 19970606; US 1997-48900 19970606; US 1997-48893 19970606; US 1997-48964 19970606; US 1997-48884 19970606; US 1997-48894 19970606; US 1997-48971 19970606; US 1997-48885 19970606; US 1997-49375 19970606; US 1997-48881 19970606; US 1997-48880 19970606; US 1997-48896 19970606; US 1997-49020 19970606; US 1997-48876 19970606; US 1997-48895 19970606.
AB The present invention relates to 207 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

L42 ANSWER 74 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1994:653685 Document No. 121:253685 Treatment of allergic responses using MHC-peptide complexes. Sharma, Somesh (Anergen, Inc., USA). PCT Int. Appl. WO 9418998 A1 19940901, 43 pp. DESIGNATED STATES: W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1994-US1919 19940224. PRIORITY: US 1993-23815 19930225.
AB The present invention is directed to complexes consisting essentially of an isolated MHC component containing and an allergenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating deleterious immune responses, such as allergic responses. The MHC component is class II MHC (e.g. HLA-DR2.2), and the peptide is recognized by a T cell associated with an allergic response to ragweed (e.g. peptide A5 of Amb a V).

L42 ANSWER 75 OF 75 CAPLUS COPYRIGHT 2005 ACS on STN
1993:403384 Document No. 119:3384 Metal binding properties of single amino acid deletion mutants of zinc finger peptides: Studies using cobalt(II) as a spectroscopic probe. Shi, Yigong; Beger, Richard D.; Berg, Jeremy M. (Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA). Biophysical Journal, 64(3), 749-53 (English) 1993. CODEN: BIOJAU. ISSN: 0006-3495.
AB Peptides correspond to Cys2His2 zinc finger domains from which one amino acid has been deleted have been synthesized and their metal-binding properties characterized. In contrast to earlier reports (Parraga, G., et al., 1990), such peptides do bind metal ions such as cobalt(II). A peptide with the sequence ProTyrLysCysProGluCysLysSerPheSerGlnLysSerAspLeu ValLysHisGlnArgThrHisThrGly (which corresponds to a previously characterized consensus zinc finger sequence from which a Gly residue immediately following the second Cys residue has been deleted) was found to form a 1:1 peptide to cobalt(II) complex with an absorption spectrum quite similar to those previously observed for zinc finger peptide-cobalt(II) complexes. The dissociation constant for this complex is 6 + 10-6 M, a factor of 100 times higher than that for the parent peptide. A peptide with the sequence LysProTyrProCysGlyLeuCysArgCysPheThrArgArgAspLeuLeuIleAr gHisAlaGlnLysIleHisSerGlyAsnLeu corresponding to a similar mutation of the peptide ADR1 was also characterized. Spectroscopic studies with cobalt(II) revealed that this peptide forms both 1:1 and 2:1 peptide to cobalt(II) complexes. The absorption spectra of the two forms and the dissociation consts. were determined via deconvolution methods. In contrast, the parent peptide ADR1a was found to form only a 1:1 complex under comparable conditions and this 1:1 complex was found to be more stable than that for the mutant. These results reveal that deletion mutations do adversely affect the stability of zinc finger peptide-metal complexes but that the effects are not as drastic as had been previously described.

```
=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        207.21    1395.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -54.75     -78.11

FILE 'REGISTRY' ENTERED AT 10:17:13 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 JUN 2005  HIGHEST RN 852656-52-1
DICTIONARY FILE UPDATES:  21 JUN 2005  HIGHEST RN 852656-52-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s [fyw][krh][fyw]c/sqsp
L43      21089 [FYW][KRH][FYW]C/SQSP

=> s l43 and 4-8/sql
        309655 4-8/SQL
L44        488 L43 AND 4-8/SQL

=> s [fyw][krh]c[fyw]c[fyw][krh][fyw]/sqsp
L45          0 [FYW][KRH]C[FYW]C[FYW][KRH][FYW]/SQSP

=> s [krh][krh][fyw]c[galivfw][fyw]c[fyw]/sqsp
L46          2 [KRH][KRH][FYW]C[GALIVFW][FYW]C[FYW]/SQSP

=> fil medl,biosis,embase,caplus;s l44 or l46
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	89.68	1485.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-78.11

FILE 'MEDLINE' ENTERED AT 10:21:03 ON 22 JUN 2005

FILE 'BIOSIS' ENTERED AT 10:21:03 ON 22 JUN 2005

FILE 'EMBASE' ENTERED AT 10:21:03 ON 22 JUN 2005

FILE 'CAPLUS' ENTERED AT 10:21:03 ON 22 JUN 2005


```
L47           0 FILE MEDLINE
L48           0 FILE BIOSIS
L49           0 FILE EMBASE
L50         112 FILE CAPLUS

TOTAL FOR ALL FILES
L51         112 L44 OR L46

=> s l51 and (l8 or l9 or rhenium or technetium)
L52           0 FILE MEDLINE
L53           0 FILE BIOSIS
L54           0 FILE EMBASE
L55           4 FILE CAPLUS

TOTAL FOR ALL FILES
L56           4 L51 AND (L8 OR L9 OR RHENIUM OR TECHNETIUM)

=> d 1-4 ibib abs hitstr
```

L56 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:59906 CAPLUS
DOCUMENT NUMBER: 142:148744
TITLE: Identification of target-specific folding sites in proteins using metallopeptide derivatives of sequences of interest
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-qun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 75 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005014193	A1	20050120	US 2003-464117		20030617
US 2004248212	A1	20041209	US 2004-769695		20040130
PRIORITY APPLN. INFO.:			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	A1	20011219
			US 2003-444129P	P	20030131
			US 2003-464117	A2	20030617

AB A method of identifying peptides that take up folded conformations and that bind to specific protein target is described. The method involves creating a systematic series of substitution derivs. of the peptide. These derivs. use amino acids or amino acid analogs containing a nitrogen or sulfur atom that can bind to a metal atom. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The structure of the metallopeptide can then be determined and a novel pharmacophore can be identified. The invention provides for defined pharmacophores of receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.

IT **7440-15-5D, Rhenium**, peptide complexes
7440-26-8D, Masurium, peptide complexes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as pharmacophores; identification of target-specific folding sites in proteins using metallopeptide derivs. of sequences of interest)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

L56 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Re

RN 7440-26-8 CAPLUS
CN Technetium (8CI, 9CI) (CA INDEX NAME)

Tc

IT **448902-19-0D**, substitution derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(as pharmacophores; identification of target-specific folding sites in proteins using metallopeptide derivs. of sequences of interest)
RN 448902-19-0 CAPLUS
CN L-Cysteinamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L56 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:637788 CAPLUS
DOCUMENT NUMBER: 137:179841
TITLE: Identification of target-specific folding sites in peptides and proteins
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002064734	A2	20020822	WO 2001-US50075		20011219
WO 2002064734	A3	20031120			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2436789	AA	20020822	CA 2001-2436789		20011219
EP 1379283	A2	20040114	EP 2001-994412		20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005501220	T2	20050113	JP 2002-565049		20011219
US 2004248212	A1	20041209	US 2004-769695		20040130
PRIORITY APPLN. INFO.:			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	W	20011219
			US 2003-444129P	P	20030131
			US 2003-464117	A2	20030617

AB The invention provides methods for identification and determination of target-specific folding sites in peptides and proteins, including a method for determining a secondary structure binding to a target of interest within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between two adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence, which includes a min. of the residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion and two residues on the amino terminus side thereof, is complexed with a metal ion, thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The invention further provides methods to det. the specific sequence and local three-dimensional structure of that portion of peptides or proteins that bind to a receptor or target of interest, or mediate a biol. activity of interest and methods to det. the pharmacophore of receptors or targets of interest. The invention provides for defined pharmacophores or receptors or targets of interest and directed libraries for identification and detn. of target-specific folding sites in peptides and proteins and for identification and detn. of pharmacophores of receptors or targets of interest.

L56 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT **7440-15-5D, Rhenium**, peptide complexes
7440-26-8D, Technetium, peptide complexes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(target-specific folding site identification in peptides and proteins)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Re

RN 7440-26-8 CAPLUS
CN Technetium (8CI, 9CI) (CA INDEX NAME)

Tc

IT **448902-19-0 448944-52-3**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(target-specific folding site identification in peptides and proteins)
RN 448902-19-0 CAPLUS
CN L-Cysteinamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448944-52-3 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:637480 CAPLUS
DOCUMENT NUMBER: 137:190724
TITLE: Melanocortin metallopeptides for treatment of sexual dysfunction
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-qun; Yang, Wei; Cai, Hui-zhi; Shadiack, Annette
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064091	A2	20020822	WO 2002-US4431	20020213
WO 2002064091	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004038897	A1	20040226	US 2003-640755	20030813
PRIORITY APPLN. INFO.:			US 2001-268591P	P 20010213
			WO 2002-US4431	A 20020213

OTHER SOURCE(S): MARPAT 137:190724
AB Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.
IT 448902-17-8 448902-17-8D, metal ion complexes
448902-19-0D, metal ion complexes 448902-28-1
448902-29-2 448902-30-5 448902-31-6
448902-34-9 448902-35-0 448902-36-1
448902-37-2 448902-38-3 448902-39-4
448902-48-5 448902-58-7 448902-64-5
448902-87-2 448902-91-8 448902-92-9
448902-93-0 448902-94-1 448902-95-2
448902-96-3 448902-97-4 448902-98-5
448902-99-6 448903-00-2 448903-01-3
448903-02-4 448903-03-5 448903-08-0
448903-14-8 448903-16-0 448903-21-7
448903-22-8 448903-30-8 448903-31-9
448903-32-0 448903-33-1 448903-34-2
448903-35-3 448903-51-3 448903-57-9
448903-60-4 448903-61-5 448903-62-6
448903-72-8 448903-73-9 448903-74-0
448903-75-1 448903-76-2 448903-77-3

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

448903-78-4 448903-79-5 448903-80-8
448903-81-9 448903-98-8 448903-99-9
448904-00-5 448904-01-6 448904-02-7
448904-03-8 448904-04-9 448904-05-0
448904-06-1 448904-10-7 448904-12-9
449729-83-3
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanocortin metallopeptides for treatment of sexual dysfunction)
RN 448902-17-8 CAPLUS
CN L-Tryptophanamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-3-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448902-17-8 CAPLUS
CN L-Tryptophanamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-3-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448902-19-0 CAPLUS
CN L-Cysteinamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-28-1 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-bromo-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-29-2 CAPLUS
CN L-Cysteinamide, (αS)-α-[(1-oxoheptyl)amino]benzenebutanoyl-4-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 448902-30-5 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-31-6 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-34-9 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-3-iodo-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-35-0 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-2-chloro-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-38-3 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-2-fluoro-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-39-4 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-3-fluoro-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-36-1 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-3-chloro-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-37-2 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-3,5-diiodo-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-48-5 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-2-chloro-D-phenylalanyl-L-lysyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-58-7 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-D-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-64-5 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-O-(phenylmethyl)-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-87-2 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-O-[(2,6-dichlorophenyl)methyl]-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448902-92-9 CAPLUS
CN L-Lysinamide, 1-(1-oxoheptyl)-L-prolyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-93-0 CAPLUS
CN L-Lysinamide, 1-(1-oxoheptyl)-D-prolyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-91-8 CAPLUS
CN L-Lysinamide, N-(1-oxoheptyl)-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-94-1 CAPLUS
CN L-Lysinamide, N-(1-oxoheptyl)-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-95-2 CAPLUS
CN L-Lysinamide, D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-96-3 CAPLUS
CN L-Lysinamide, L-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-97-4 CAPLUS
CN L-Tryptophanamide, L-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448902-98-5 CAPLUS
CN L-Tryptophanamide, D-phenylalanyl-L-arginyl-D-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448902-99-6 CAPLUS
CN L-Lysinamide, L-phenylalanyl-L-arginyl-D-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-00-2 CAPLUS
CN L-Lysinamide, D-phenylalanyl-L-arginyl-D-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-01-3 CAPLUS
CN L-Tryptophanamide, L-phenylalanyl-L-arginyl-D-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-02-4 CAPLUS
CN L-Lysinamide, D-phenylalanyl-L-arginyl-L-tryptophyl-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-03-5 CAPLUS
CN L-Lysinamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 448903-08-0 CAPLUS
CN L-Tryptophanamide, D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-14-8 CAPLUS
CN L-Tryptophanamide, D-phenylalanyl-L-arginyl-L-tryptophyl-D-cysteinyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-16-0 CAPLUS
CN L-Cysteinamide, N-(7-amino-1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-21-7 CAPLUS
CN L-Cysteinamide, O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-D-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-22-8 CAPLUS
CN L-Cysteinamide, N-(7-amino-1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-D-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-30-8 CAPLUS
CN L-Cysteinamide, N-acetyl-L-norleucyl-L-alanyl-L-histidyl-3-[1,1'-biphenyl]-4-yl-D-alanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-31-9 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-3-[1,1'-biphenyl]-4-yl-D-alanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-32-0 CAPLUS
CN L-Cysteinamide,
N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-3-[1,1'-biphenyl]-4-yl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-33-1 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-3-[1,1'-biphenyl]-4-yl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-34-2 CAPLUS
CN L-Cysteinamide,
N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-3-[1,1'-biphenyl]-4-yl-D-alanyl-L-arginyl-3-[1,1'-biphenyl]-4-yl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-35-3 CAPLUS
CN L-Cysteinamide,
N-acetyl-L-norleucyl-L-alanyl-L-histidyl-3-[1,1'-biphenyl]-4-yl-D-alanyl-L-arginyl-3-[1,1'-biphenyl]-4-yl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-51-3 CAPLUS
CN L-Cysteinamide,
(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-4-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-57-9 CAPLUS
CN L-Cysteinamide, N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-60-4 CAPLUS
CN L-Cysteinamide,
(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-2-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-61-5 CAPLUS
CN L-Cysteinamide,
(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-3-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-62-6 CAPLUS
CN L-Cysteinamide, (3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-72-8 CAPLUS
CN L-Cysteinamide, (1R)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-75-1 CAPLUS
CN L-Cysteinamide, 1-aminocyclopentanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-76-2 CAPLUS
CN L-Cysteinamide,
2-amino-2,3-dihydro-1H-indene-2-carbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-73-9 CAPLUS
CN L-Cysteinamide, (1S)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448903-74-0 CAPLUS
CN L-Cysteinamide, 1-aminocyclohexanecarbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448903-77-3 CAPLUS
CN L-Cysteinamide, 3-(1-naphthalenyl)-L-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448903-78-4 CAPLUS
CN L-Cysteinamide, 3-(1-naphthalenyl)-D-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448903-79-5 CAPLUS
CN L-Cysteinamide, 3-(2-naphthalenyl)-L-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448903-80-8 CAPLUS
CN L-Cysteinamide, 3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 448903-81-9 CAPLUS
CN L-Cysteinamide, D-prolyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 448903-98-8 CAPLUS
CN L-Cysteinamide, 3-[1,1'-biphenyl]-4-yl-L-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 448903-99-9 CAPLUS
CN L-Cysteinamide, (2S)-2,3-dihydro-1H-indole-2-carbonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448904-00-5 CAPLUS
CN L-Cysteinamide, N-[4-(aminomethyl)benzoyl]-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 448904-01-6 CAPLUS
CN L-Cysteinamide, L-prolyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448904-02-7 CAPLUS
CN L-Cysteinamide,
(2R)-2-(2,3-dihydro-1H-inden-2-yl)glycyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448904-03-8 CAPLUS
CN L-Cysteinamide,
(2S)-2-(2,3-dihydro-1H-inden-2-yl)glycyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448904-04-9 CAPLUS
CN L-Cysteinamide,
N-[(phenylmethoxy)carbonyl]-3-(1H-pyrazol-1-yl)-D-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448904-05-0 CAPLUS
CN L-Cysteinamide, β-phenyl-D-phenylalanyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448904-06-1 CAPLUS
CN L-Cysteinamide, L-allothreonyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 448904-10-7 CAPLUS
CN L-Cysteinamide, (2R)-N-(7-amino-1-oxoheptyl)-2-(2,3-dihydro-1H-inden-2-yl)glycyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—NH_2

IT 7440-15-5D, Rhenium, peptide complexes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanocortin metallopeptides for treatment of sexual dysfunction)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Re

L56 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 448904-12-9 CAPLUS
CN L-Cysteinamide, O-(phenylmethyl)-L-seryl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449729-83-3 CAPLUS
CN L-Cysteinamide, N-[[4-(aminomethyl)cyclohexyl]carbonyl]-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:137478 CAPLUS
DOCUMENT NUMBER: 134:188233
TITLE: Melanocortin metallopeptide constructs, combinatorial libraries, and applications
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Yang, Wei; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013112	A1	20010222	WO 2000-US16396	20000615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379647	AA	20010222	CA 2000-2379647	20000615
EP 1208377	A1	20020529	EP 2000-944681	20000615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2004519410	T2	20040702	JP 2001-517163	20000615
PRIORITY APPLN. INFO.:			US 1999-148994P	P 19990812
			WO 2000-US16396	W 20000615

OTHER SOURCE(S): MARPAT 134:188233

AB Metallopeptides and metallopeptide combinatorial libraries specific for melanocortin receptors are provided, for use in biol., pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion.

IT 327606-65-5P 327606-66-6P 327606-67-7P
327606-81-5P 327606-87-1P 327608-40-2P
327608-41-3P 327608-54-8P 327608-55-9P
327608-56-0P 327608-57-1P 327608-58-2P
327608-59-3P 327608-60-6P 327608-61-7P
327608-62-8P 327608-72-0P 327608-80-0P
327608-81-1P 327608-82-2P 327608-83-3P
327608-84-4P 327608-90-2P 327608-91-3P
327608-92-4P 327608-93-5P 327608-94-6P
327608-95-7P 327608-96-8P 327608-97-9P
327608-98-0P 327608-99-1P 327609-18-7P
327609-19-8P 327609-20-1P 327609-21-2P
327609-22-3P 327609-30-3P 327609-31-4P
327609-34-7P 327609-48-3P 327609-58-5P
327609-59-6P 327609-60-9P 327609-61-0P
327609-62-1P 327609-65-4P 327609-67-6P

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

327609-68-7P 327609-69-8P 327609-70-1P
327609-71-2P 327609-82-5P 327609-84-7P
327609-90-5P 327609-91-6P 327610-07-1P
327624-36-2P 327625-99-0P 327626-00-6P
327626-08-4P 327626-10-8P 327626-11-9P
327626-18-6P 327626-21-1P 327626-22-2P
327626-23-3P 327626-32-4P 448944-52-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanocortin metallopeptide constructs, combinatorial libraries, and applications)

RN 327606-65-5 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-D-tryptophyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327606-66-6 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327606-67-7 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-D-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327606-81-5 CAPLUS
CN Rhenate(1-), [N-acetyl-L-tryptophyl-D-arginyl-κN2-L-phenylalanyl-κN-L-cysteinyl-κN,κS-L-norleucinamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 327606-87-1 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 327608-54-8 CAPLUS
CN Rhenate(1-), [N-acetyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 327608-40-2 CAPLUS
CN Rhenate(1-), [N-acetyl-L-arginyl-L-phenylalanyl-L-ornithyl-κN2-4-chloro-D-phenylalanyl-κN-L-cysteinyl-κN,κS-L-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 327608-41-3 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-phenylalanyl-L-ornithyl-κN2-4-chloro-D-phenylalanyl-κN-L-cysteinyl-κN,κS-L-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 327608-55-9 CAPLUS
CN Rhenate(1-), [1-acetyl-L-prolyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 327608-56-0 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinyl-κN,κS-L-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● H+

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 327608-57-1 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinyl-κN,κS-L-leucinamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-58-2 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinyl-κN,κS-L-lysinamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-59-3 CAPLUS
CN Rhenate(1-), [1-acetyl-L-prolyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-60-6 CAPLUS

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Rhenate(1-), [1-acetyl-L-prolyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinyl-κN,κS-D-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327608-61-7 CAPLUS

CN Rhenate(1-), [(3R)-2-acetyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327608-62-8 CAPLUS

CN Rhenate(1-), [N-acetyl-4-benzoyl-D-phenylalanyl-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327608-72-0 CAPLUS

CN Rhenate(1-), [N-acetyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinyl-κN,κS-L-lysyl-L-prolyl-L-valinamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—Pr-i

—NH_2

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H^+

RN 327608-80-0 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H^+

RN 327608-81-1 CAPLUS
CN Rhenate(1-), [N-benzoyl-L-histidylglycyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H^+

RN 327608-82-2 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-D-tryptophyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H^+

RN 327608-83-3 CAPLUS
CN Rhenate(1-), [N-acetyl-L-alanyl-L-histidyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-84-4 CAPLUS

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Rhenate(1-), [N-benzoyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327608-90-2 CAPLUS

CN Rhenate(1-), oxo[N-(1-oxoheptyl)-L-tyrosyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-91-3 CAPLUS

CN Rhenate(1-), oxo[N-(1-oxoheptyl)-L-tryptophyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-92-4 CAPLUS

CN Rhenate(1-), [3-(2-naphthalenyl)-N-(1-oxoheptyl)-L-alanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-93-5 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-α-phenyl-L-phenylalanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327608-94-6 CAPLUS
CN Rhenate(1-), [3,4-dichloro-N-(1-oxoheptyl)-L-phenylalanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-95-7 CAPLUS
CN Rhenate(1-), [4-methyl-N-(1-oxoheptyl)-L-leucyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327608-96-8 CAPLUS
CN Rhenate(1-), [3-cyclohexyl-N-(1-oxoheptyl)-L-alanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327608-97-9 CAPLUS
CN Rhenate(1-), {4-nitro-N-(1-oxoheptyl)-L-phenylalanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327608-98-0 CAPLUS

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Rhenate(1-), oxo[(αS)-α-{(1-oxoheptyl)amino]benzenebutanoyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327608-99-1 CAPLUS
CN Rhenate(1-), oxo[(3S)-1,2,3,4-tetrahydro-2-(1-oxoheptyl)-3-isoquinolinecarbonyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327609-18-7 CAPLUS
CN Rhenate(1-), [N-acetyl-O-(phenylmethyl)-L-seryl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-19-8 CAPLUS
CN Rhenate(1-),
[N-benzoyl-O-(phenylmethyl)-L-seryl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-22-3 CAPLUS
CN Rhenate(1-),
[N6-benzoyl-N2-(1-oxoheptyl)-L-lysyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-30-3 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-3-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 327609-20-1 CAPLUS
CN Rhenate(1-),
oxo[N2-(1-oxoheptyl)-L-asparaginyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● H+

RN 327609-21-2 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-L-α-asparty1-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(5-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-31-4 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-3,4-dichloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327609-34-7 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-48-3 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxo-4-phenylbutyl)-O-(phenylmethyl)-L-seryl-N-methyl-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-58-5 CAPLUS
CN Rhenate(1-), [3-(benzoylamino)-N-(1-oxoheptyl)-L-alanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-59-6 CAPLUS
CN Rhenate(1-), [3-[(2-naphthalenylacetyl)amino]-N-(1-oxoheptyl)-L-alanyl-2-

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● H+

RN 327609-60-9 CAPLUS

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-3-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-L-alanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● H+

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 327609-61-0 CAPLUS

CN Rhenate(1-), [3-[[(4-methylphenyl)acetyl]amino]-N-(1-oxoheptyl)-L-alanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 327609-62-1 CAPLUS

CN Rhenate(1-), [3-[[(3-bromophenyl)acetyl]amino]-N-(1-oxoheptyl)-L-alanyl-2-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 327609-65-4 CAPLUS

CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-2-chloro-D-phenylalanyl-L-arginyl-κN2-β-phenyl-L-phenylalanyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 327609-67-6 CAPLUS

CN Rhenate(1-), oxo[D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



RN 327609-68-7 CAPLUS

CN Rhenate(1-), [N-acetyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-69-8 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-70-1 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-71-2 CAPLUS
CN Rhenate(1-), [1-acetyl-L-prolyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-82-5 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-fluoro-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-84-7 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-2-bromo-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327609-90-5 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-(trifluoromethyl)-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327609-91-6 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-methyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327610-07-1 CAPLUS
CN Rhenium, oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● H+

RN 327624-36-2 CAPLUS
CN Rhenium, oxo[N-(1-oxoheptyl)-L-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, (SP-5-24)-(9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327625-99-0 CAPLUS
CN Rhenate(1-), [(3R)-2-acetyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327626-00-6 CAPLUS
CN Rhenate(1-), [(3S)-2-acetyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



● H+

RN 327626-08-4 CAPLUS
CN Rhenate(1-), [1-acetyl-L-prolyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 327626-10-8 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-D-cysteinyl-κN,κS-L-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 327626-11-9 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinyl-κN,κS-D-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 327626-18-6 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-D-cysteinyl-κN,κS-D-tryptophanamidato(4-)]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 327626-21-1 CAPLUS
CN Rhenate(1-), oxo(N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-2-chloro-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327626-22-2 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-D-phenylalanyl-L-arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 327626-23-3 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-4-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
arginyl-κN2-L-tryptophyl-κN-L-cysteinamidato(4-)-κN,κS]oxo-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● H+

IT 7440-15-5D, Rhenium, complexes with peptidic compds., biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(melanocortin metallopeptide constructs, combinatorial libraries, and applications)
RN 7440-15-5 CAPLUS
CN Rhenium (8CI, 9CI) (CA INDEX NAME)

Re

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● H+

RN 327626-32-4 CAPLUS
CN Rhenate(1-), oxo[N-(1-oxoheptyl)-O-(phenylmethyl)-L-seryl-3-chloro-D-phenylalanyl-L-arginyl-κN2-D-tryptophyl-κN-L-cysteinamidato(4-)-κN2,κS]-, hydrogen, (SP-5-24)- (9CI) (CA INDEX NAME)



● H+

RN 448944-52-3 CAPLUS
CN Rhenate(1-), [N-acetyl-L-norleucyl-L-alanyl-L-histidyl-D-phenylalanyl-L-

L56 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

```
=> dis his

     (FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 10:00:47 ON 22 JUN
     2005)
                DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 10:04:51 ON 22 JUN 2005
L1                  STR
L2               50 S L1
L3                  STR L1
L4                  STR L1
L5               50 S L3 OR L4
L6            27910 S L3 OR L4 FUL

     FILE 'CAPLUS' ENTERED AT 10:11:11 ON 22 JUN 2005
L7             9226 S L6

     FILE 'REGISTRY' ENTERED AT 10:11:27 ON 22 JUN 2005
                  E RHENIUM/CN 5
L8                1 S E3
                  E TECHNETIUM/CN 5
L9                1 S E3

     FILE 'CAPLUS' ENTERED AT 10:12:25 ON 22 JUN 2005
L10            173 S L7 AND (L8 OR L9 OR RHENIUM OR RE OR TECHNETIUM OR TC)

     FILE 'CAPLUS' ENTERED AT 10:12:41 ON 22 JUN 2005
L11            133 S L7 AND (L8 OR L9 OR RHENIUM OR  TECHNETIUM )
L12              4 S (ELANOCORTIN METALLOPEPIDE OR COMBINATOR? LIBRAR?) AND L11
L13              4 S (MELANOCORTIN METALLOPEPIDE OR COMBINATOR? LIBRAR?) AND L11

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 10:15:10 ON 22 JUN 2005
L14            4135 FILE MEDLINE
L15            6562 FILE BIOSIS
L16            3621 FILE EMBASE
L17            6387 FILE CAPLUS
     TOTAL FOR ALL FILES
L18           20705 S SHARMA S?/AU
L19            2041 FILE MEDLINE
L20            2302 FILE BIOSIS
L21            1535 FILE EMBASE
L22            6286 FILE CAPLUS
     TOTAL FOR ALL FILES
L23           12164 S SHI Y?/AU
L24            1104 FILE MEDLINE
L25            1290 FILE BIOSIS
L26             872 FILE EMBASE
L27            4438 FILE CAPLUS
     TOTAL FOR ALL FILES
L28            7704 S WEI Y?/AU
L29             413 FILE MEDLINE
L30             515 FILE BIOSIS
L31             304 FILE EMBASE
L32            1330 FILE CAPLUS
     TOTAL FOR ALL FILES
L33            2562 S CAI H?/AU
L34               0 FILE MEDLINE
```

```
L35             0 FILE BIOSIS
L36             0 FILE EMBASE
L37             0 FILE CAPLUS
     TOTAL FOR ALL FILES
L38             0 S L18 AND L23 AND L28 AND L33

     FILE 'CAPLUS' ENTERED AT 10:15:50 ON 22 JUN 2005
L39            78 S L7 AND (L18 OR L23 OR L28 OR L33)
L40             3 S (MELANOCORTIN METALLOPEPIDE OR COMBINATOR? LIBRAR?) AND L39
L41             0 S L40 NOT L13
L42            75 S L39 NOT L40

     FILE 'REGISTRY' ENTERED AT 10:17:13 ON 22 JUN 2005
L43         21089 S [FYW][KRH][FYW]C/SQSP
L44           488 S L43 AND 4-8/SQL
L45             0 S [FYW][KRH]C[FYW]C[FYW][KRH][FYW]/SQSP
L46             2 S [KRH][KRH][FYW]C[GALIVFW][FYW]C[FYW]/SQSP

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 10:21:03 ON 22 JUN 2005
L47             0 FILE MEDLINE
L48             0 FILE BIOSIS
L49             0 FILE EMBASE
L50           112 FILE CAPLUS
     TOTAL FOR ALL FILES
L51           112 S L44 OR L46
L52             0 FILE MEDLINE
L53             0 FILE BIOSIS
L54             0 FILE EMBASE
L55             4 FILE CAPLUS
     TOTAL FOR ALL FILES
L56             4 S L51 AND (L8 OR L9 OR RHENIUM OR TECHNETIUM)

=> d l6 que stat
L3                STR
```








```
VAR G1=19/29
NODE ATTRIBUTES:
```

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L4 STR





VAR G1=19/29
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L6 27910 SEA FILE=REGISTRY SSS FUL L3 OR L4

100.0% PROCESSED 138233 ITERATIONS 27910 ANSWERS
SEARCH TIME: 00.00.02

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	56.51	1541.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-81.03

STN INTERNATIONAL LOGOFF AT 10:22:42 ON 22 JUN 2005

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86